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ABSTRACT
Aims: To examine the associations between intentional weight loss and health-related
quality of life (HRQL) among obese patients.
Methods: The total number of patients studied was 474 (41% male, mean age 48.4 y,
and mean BMI 38.7 kg/m
2). HRQL was measured with questionnaires (RAND-36/SF-
36 Health Survey and Obesity-related problems scale) at baseline and repeatedly
during follow-up. Studies I and II were based on a randomised clinical trial with obese
men (n=38). The treatment group lost weight during 10 weeks on VLED and 4 months
of behaviour modification. There was no intervention for the control group. The follow-
up time after treatment was four months. Study III included 126 obese outpatients
entering the treatment programme identical to study I. The follow-up time was two
years after the treatment. Study IV was a randomised placebo-controlled trial of
sibutramine (n=236) in obese patients with type 2 diabetes. The follow-up time was one
year. Study V included 74 obese patients undergoing either gastric bypass (n=48) or
vertical banded gastroplasty (n=26). The post-operative follow-up time was one year.
Results: Baseline HRQL was markedly poorer in obese patients than in healthy Finns.
In studies I and II, the mean weight loss at eight months was 13.9% in the treatment
group, the control group was weight stable. There was transient improvement in many
RAND-36 scales during the treatment. The improvement in physical functioning, social
functioning, and obesity-related psychosocial problems was maintained until the end of
follow-up. Despite the weight loss and increase in serum testosterone level, the scores
on sexual functions did not change. In study III, the weight loss among completers was
12.5% at the end of treatment, 6.0% at one year, and 2.6% at two years. All the HRQL
scales improved markedly during treatment, but as weight was regained the scores
started to decrease. At two years there was maintained improvement in physical
functioning and obesity-related psychosocial problems. ≥ 10% maintained weight loss
was associated with a cluster of HRQL benefits. In study IV, the weight loss was
significantly larger in the sibutramine group (7.3%) than in the placebo group (2.4%) at
one year. There was no significant difference in any RAND-36 score between groups
during the follow-up. Both groups reported improvement in physical functioning and
global assessment of health-change since last year. Improvement in glycaemic control
was correlated to HRQL improvement. ≥ 15% maintained weight loss was associated
with a cluster of HRQL improvements. Those with good emotional role functioning and
good social functioning at baseline and improvement in physical functioning and vitality
during the first 3 months of study achieved the largest weight loss at one year. In study
V, the weight loss at one year was 34.0% and 26.1% for gastric bypass and vertical
banded gastroplasty, respectively. During follow-up all SF-36 scores increased
markedly in both groups. ≥ 50% of patients reported optimal HRQL in physical
functioning, physical role functioning, bodily pain, emotional role functioning, and social
functioning at one year postoperatively.
Conclusions: Poor HRQL was improved with intentional weight loss. HRQL responses
were dependent on the amount of weight loss: 5-10% weight loss was needed to
improve physical functioning and obesity-related psychosocial problems, and >10-15%
was needed to achieve a cluster of HRQL improvements. Other factors such as
increase in physical activity, improvement in glycaemic control, and the therapeutic
effect of participating in the treatment programme may affect HRQL responses. Some
HRQL measures were predictive of success in weight loss maintenance.
Key words: obesity, weight loss, health-related quality of life, RAND-36, SF-36, OP
scale, IIEF, SAS, VLED, behaviour modification, sibutramine, gastric bypass, vertical
banded gastroplasty9
1 INTRODUCTION
The prevalence of obesity is increasing worldwide. Among 25-64 year-old Finns, 19.8%
of men and 19.4% of women had a BMI ≥ 30 kg/m
2 in 1997 (Lahti-Koski et al. 2000a).
The most alarming trend is the increasing prevalence of abdominal obesity (Lahti-Koski
et al. 2000b), which is strongly associated with the metabolic syndrome and type 2
diabetes. Obesity is also associated with several other chronic conditions, such as
coronary heart disease, obstructive sleep apnoea, asthma and other pulmonary
syndromes, degenerative joint disease, and certain types of cancer. On a societal level
the health risks associated with obesity pose a serious and costly public health hazard.
On an individual level obesity not only shortens life expectancy but also reduces the
number of healthy and functional life-years (WHO 2000).
Quality of life is a broad concept including physical, mental, and social well-being.
Health-related quality of life is a narrower concept including attempts to define the
impact of diseases and their treatments on functional status and well-being (Testa and
Simonson 1996). The basic principle of measuring quality of life is that the patient is
asked what he/she can do (functioning) and how he/she feels (well-being). Information
on HRQL may influence the development of clinical pathways, service provision, health
care expenditures, and public health policy.
If obese, only 5-10% maintained weight loss has been shown to improve metabolism
and to reduce the risk of obesity-related chronic conditions. If already diagnosed,
weight loss improves the symptoms and clinical findings of these obesity-related
chronic conditions (Mustajoki et al. 2002). But how do the patients themselves rate
their functioning and well-being?
This thesis is based on self-administered questionnaires and it examines the patient
perspective on associations of weight loss and health-related quality of life in clinical
weight loss studies. The weight loss methods include very-low-energy diet and
behaviour modification, the weight loss drug sibutramine, and weight loss surgery using
gastric bypass or vertical banded gastroplasty. First, HRQL in the clinical obese
populations entering weight loss programmes is evaluated. Then, the changes in
HRQL during active weight loss, and more importantly, during longer-term weight loss
maintenance are reported. This thesis also presents data on HRQL measures as
predictors of success in weight loss maintenance over 1-2 years.10
2  REVIEW OF THE LITTERATURE
2.1 Obesity
Obesity stands for excess body fat. The exact amount of body fat is difficult to
measure. Therefore, the easy-to-measure BMI is the most widely used surrogate
marker for body fat content. The BMI is body weight (kg) divided by height squared
(m
2). Quetelet, a statistician who worked in the middle of the 19
th century, introduced
BMI as the best index for comparing populations (Quetelet 1835). Increasing degree of
BMI is associated with increasing prevalence of hypertension, the metabolic syndrome,
type 2 diabetes, coronary heart disease, and numerous other obesity-related chronic
conditions (National Task Force 2000a). The BMI cut-off values presented in table 1
are independent of age and sex in adults. BMI is a crude risk estimate, a range of other
factors (e.g. diet, physical activity, ethnicity) contribute to the disease and mortality risk.
BMI does not distinguish between lean body mass, oedema, and fat mass. BMI also
fails to measure body fat distribution: it doesn’t show where the excess fat is situated in
the body. Since the 1950´s it has been clear, that android type obesity (upper body fat
accumulation/abdominal obesity) poses higher disease risk than gynoid type obesity
(lower body fat accumulation) (Vague 1956). Abdominal fat consists of abdominal
subcutaneous fat and intra-abdominal fat. The most commonly used surrogate markers
of intra-abdominal fat are waist-to-hip ratio (Seidell et al. 1987) and waist
circumference (Lemieux et al. 1996). Abdominal obesity is associated with obesity-
related metabolic complications (hypertension, hyperinsulinaemia, type 2 diabetes,
dyslipidaemia, the metabolic syndrome) and cardiovascular diseases (National Task
Force 2000a). There is no general consensus on the appropriate cut-off points for waist
circumference among different ethnic populations, but table 2 presents widely used
values for Caucasian populations (Han et al. 1995). The Finnish guidelines for obesity
management recommend cut-off points that are easier to remember in everyday
practice: 100 cm for men and 90 cm for women (Mustajoki et al. 2002).
The prevalence of obesity is rapidly increasing worldwide. In the USA, the prevalence
of obesity (BMI ≥ 30 kg/m
2) in 2001 was 20.9% vs. 19.8% in 2000, an increase of 5.6%
in only one year (Mokdad et al. 2003). Since the 1970´s regular population surveys
assessing the trend of overweight and obesity in Finland have been carried out. The
prevalence of obesity has increased both in men and women, especially among young
adults and older men: the prevalence of obesity (BMI ≥ 30 kg/m
2) among men was
15.4% in 1982 and 19.8% in 1997 and among women 17.2% and 19.4%, respectively
(Lahti-Koski et al. 2000a). Also the prevalence of abdominal obesity has increased.
The proportion of men with waist-to-hip ratio ≥ 1.00 was 8.3% in 1987 and 14.3% in
1997. The proportion of women with waist-to-hip ratio ≥ 0.85 was 12.6% in 1987 and
20.1% in 1997 (Lahti-Koski 2001).11
Table 1. Classification of overweight and obesity according to BMI (WHO 2000).
Classification BMI (kg/m
2) Risk of obesity-related
comorbidity
Underweight < 18.5 Low
Normal 18.5-24.9 Average
Overweight 25.0-29.9 Increased
Obese, class I 30.0-34.9 Moderate
Obese, class II 35.0-39.9 Severe
Obese, class III ≥  40.0 Very severe
Table 2. The suggested sex-specific cut-off points for waist circumference based on a
study among the Dutch (Han et al. 1995).
Risk of obesity-related metabolic complications
Increased Substantially increased
Men ≥  94 cm ≥  102 cm
Women ≥  80 cm ≥  88 cm
The association between BMI or waist circumference and risk factors, morbidity, and
mortality is continuous; therefore all attempts to identify cut-off points are arbitrary.
However, cut-off points are feasible when comparing different populations or population
subgroups. At the individual level, the classification of obesity is useful in estimating
disease risk, assessing the need to treat obesity, choosing the suitable treatment
modality, and following the success of treatment.
2.2  Obesity and related health problems
2.2.1  Metabolic syndrome and type 2 diabetes
Fat tissue is the largest hormonally and metabolically active organ in the human body.
Of particular importance is the role fat tissue plays in association with risk factors for
cardiovascular diseases (e.g. hypertension, type 2 diabetes, and dyslipidaemia). The
association between obesity and these risk factors has been examined in numerous
observational studies.
The risk of both systolic and diastolic hypertension increases with increasing BMI and
abdominal obesity (Blair et al. 1984, MacMahon et al. 1987). Weight gain increases the
risk of becoming hypertensive (Field et al. 1999). A Finnish study showed that blood
pressure increased linearly with increasing BMI and in normotensive subjects BMI
predicted the future development of hypertension (Jousilahti et al. 1995). Obesity and
weight gain during adulthood are associated with increased risk of developing insulin
resistance and hyperinsulinaemia (Lakka H-M et al. 2002a). Obesity is also associated
with dyslipidaemia, in particular with high plasma triglyceride levels and low HDL
cholesterol levels (Després et al. 1991). The proportion on small, dense LDL particles
is also increased (Lamarce et al. 1999).12
The above mentioned risk factors form a complex cluster, which is called the metabolic
syndrome. The definition of this syndrome usually includes the presence of abdominal
obesity, insulin resistance (with or without glucose intolerance), atherogenic
dyslipidaemia (high triglyceride, small LDL particles, and low HDL cholesterol), raised
blood pressure, and prothrombotic and proinflammatory states (Alberti 1998, Expert
Panel/NCEP 2001). In a Finnish town of Pieksämäki, the prevalence of the metabolic
syndrome in middle age was 17% in men and 8% in women (Vanhala 1996). The
prevalence was only 2-4% in normal weight subjects, but 14-20 fold higher among
those with both obesity and abdominal obesity. In the Botnia study, the prevalence of
the metabolic syndrome was 15% in men and 10% in women with normal glucose
tolerance, 64% in men and 42% in women with impaired fasting glucose/impaired
glucose tolerance, and 84% in men and 78% in women with type 2 diabetes (Isomaa et
al. 2001). In a recent Finnish study among men, the prevalence of the metabolic
syndrome was 8.8-14.3% depending on the definition of the syndrome (Lakka H-M et
al. 2002b). Over the 11-year follow-up period, men with the metabolic syndrome were 3
to 4 times more likely to die of coronary heart disease and 2 times likely to die of any
cause.
Insulin resistance and its progressive deterioration form hyperinsulinaemia with normal
fasting glucose to impaired fasting glucose and finally fasting hyperglycaemia lead to
the clinical diagnosis of type 2 diabetes. Obesity and especially abdominal obesity
have a deleterious effect on all phases of this process. Several observational studies
have documented the association between BMI, weight gain and the incidence of type
2 diabetes (e.g. Chan et al. 1994, Wannamethee et al. 1999). Since the prevalence of
obesity is increasing, also the prevalence of type 2 diabetes is increasing. In the USA,
the prevalence of diabetes increased to 7.9% in 2001 vs. 7.3% in 2000, an increase of
8.2% in only one year (Mokdad et al. 2003). It was recently estimated in the USA, that
the lifetime risk of developing diabetes for individuals born in 2000 is 32.8% for men
and 38.5% for women (Venkat Narayan et al. 2003).
2.2.2  Testosterone and sexual functions
Ageing changes body composition: central fat mass increases and skeletal muscle
mass decreases (Seidell and Visscher 2000). Ageing also decreases both total and
free testosterone levels independent of obesity; about 1/10 of the men in their 50's and
1/3 in their 60's are hypogonadal (Harman 2001). An inverse association of total
testosterone, free testosterone and SHBG with visceral fat is well established (Haffner
2000). Low testosterone and SHBG levels are strongly associated not only with
components of the metabolic syndrome, but also with the metabolic syndrome itself,
independently of BMI (Laaksonen et al. 2003a). Moreover, hypoandrogenism predicts
the development of type 2 diabetes (Abate et al. 2002).
There is limited information on the prevalence of sexual dysfunction in the general
population and in obese subjects. In a Swedish population study, loss of male erectile
function was as common in diabetes (30%) as in angina pectoris (29%) and13
significantly higher than in the general population (20%) (Wändell and Brorsson 2000).
Few case-reports of decreased libido and impotence in extremely obese men have
been published (Blum et al. 1988), but no relationship between obesity and
abnormalities in libido were apparent in a larger study (Strain 1982).
2.2.3 Chronic  conditions
Evidence from long-term observational studies indicates that obesity is a predictor of
cardiovascular atherosclerosis independent of its effects on traditional risk factors.
Several studies have shown the association between obesity and coronary heart
disease in both sexes (Hubert et al. 1983, Manson et al. 1990, Jousilahti et al. 1996).
Obesity also increases the risk of ischaemic stroke (Walker et al. 1996, Rexrode et al.
1997).
Obesity increases the risk of numerous other chronic conditions, such as gallstones,
steatohepatosis, reproductive problems, obstructive sleep apnoea, asthma, poor
pulmonary function, and degenerative joint disease (National Task Force 2000a).
Obesity also increases the risk of certain types of cancer. The association is clear with
colon, postmenopausal breast, endometrial, prostate, kidney, and oesophageal
cancers (IARC 2002). The obesity-related somatic diseases and conditions are
summarised in table 3.
2.2.4 Psychopathology
Obesity is the most common somatic and depression is the most common
psychological illness in our society. Studies have shown an increase in the prevalence
of psychopathology in obese subjects (Leon and Roth 1977, Goldstein et al. 1996,
Carpenter et al. 2000). This association may be due to the stigmatisation and
discrimination the obese suffer from (Rand and Macgregor 1990, Stunkard and
Wadden 1992, Lewis et al. 1997). Repeated but failed attempts to lose weight may be
accompanied by thoughts of quilt, hopelessness, and poor self-esteem (Wooley and
Garner 1991). Obesity is also associated with a high prevalence of binge-eating
disorder, which is often coexistent with depression (de Zwaan 2001). The serious
somatic comorbidities associated with obesity may further aggravate mental health
(Doll et al. 2000). Which comes first? Depression may also be a cause of obesity. At
least depression in children has been associated with adult obesity (Pine et al. 2001).
Also the medication used to treat depression may cause weight gain (Fava 2000).
However, the SOS-study reported that among the severely obese psychological
morbidity was more common than in the reference population. Mental well-being was
worse, and anxiety and depressive symptoms were more common: 20-25% of the
severely obese reported scores exceeding the level of probable severe anxiety and
about 10% the level of severe depression. Women reported worse current health and
mental well-being than men (Sullivan et al. 1993).14
Table 3. Obesity-related somatic diseases and conditions.
Cardiovascular system  Locomotive system
Coronary heart disease  Osteoarthrosis
Left ventricular hypertrophy  Chronic pain
Heart failure  Sexual and reproductive systems
Arrhythmia Menstrual  irregularity
Sudden death Reduced fertility
Stroke Hypogonadism among men
Pulmonary hypertension   Polycystic ovary syndrome
Venous thrombosis Skin
Thromboembolism Hirsutism
Respiratory system Striae
Obstructive sleep apnea Acantosis nigrans
Pickwickian syndrome Cancer
Asthma Endometrium
Metabolic disorders Prostate
Metabolic syndrome Postmenopausal breast
Insulin resistance Kidney
Type 2 diabetes Oesophagus
Hyperuricaemia and gout Liver
Liver and biliary system Colon
Fatty liver  Anaesthesia and surgery complications
Gall stones
2.2.5 Mortality
Most studies have documented U-, reversed J-, and J-shaped associations between
BMI and mortality in both sexes: all-cause mortality increases with both higher and
lower BMI values in the general population. One study found an U-shaped association
in middle-aged men, but a reversed J-shape in women (Waaler 1988). Another
documented an U-shaped association among men, but not in women (Seidell et al.
1996). Fatal diseases causing low body weight (e.g. cancer or smoking-related
diseases) explain the excess mortality at the lower BMI range. The gender differences
may be explained by a greater tendency for males to develop abdominal obesity.
Numerous factors (e.g. age, life-style, and socio-economic status) can modify the
relationship between obesity and all-cause mortality. Fitness is a strong modifier of this
association: lean, but unfit men have a higher risk of all-cause and cardiovascular
disease mortality than do men who are fit and obese (Lee et al. 1999). However,
obesity shortens life expectancy: White men aged 20 to 30 years with morbid obesity
(BMI >45 kg/m
2) are estimated to lose 13 years of life and women 8 years (Fontaine et
al. 2003).
2.2.6  Costs of obesity
Obesity-related chronic conditions cause direct and indirect health care costs.
Increasing BMI associates with increasing medical service use, such as medication
use, visits to hospital emergency departments, doctor visits, and visits to outpatient
clinics (Guallar-Castillion et al. 2002, Reidpath et al. 2002). The obese take more often
medication for diabetes, cardiovascular disease, chronic pain, and asthma compared to15
the reference population, and the annual cost for all medications was on average US$
140 in obese individuals and US$ 80 in the reference population (Narbro et al. 2002).
A recent systematic review suggests that obesity accounts for 5.5-7.0% of national
health expenditures in the United States and 2.0-3.5% in other countries (Thompson
and Wolf 2001). In the USA, the annual obesity-attributable medical expenditures were
estimated at US$ 75 billion (Finkelstein et al. 2004). In Finland it was estimated that
obesity caused a health-care cost of €0.15-0.54 billion in 1997 (Pekurinen et al. 2000).
This was more than the health-care costs related to smoking. The indirect costs of
obesity (loss of productivity due to premature death and disability from obesity-related
illness) are likely to be even larger than the direct costs.
Data from Sweden show that the number of days on sick leave and the frequency of
disability pensions are almost doubled in obese subjects compared to the general
population (Narbro et al. 1996). In Finland, obesity predicted work disability, and the
risk was increased linearly with BMI (Rissanen et al. 1990). On the other hand, obese
individuals themselves would be willing to pay approximately twice their monthly salary
for effective treatment. The higher the weight and the poorer the perceived health, the
higher the willingness to pay (Narbro and Sjöström 2000).
2.3  Management of obesity
2.3.1  Diet, physical activity, and behaviour modification
The current obesity epidemic may be a result of the resent changes in environment
(increased availability of energy-dense foods and decreased physical activity) (Jeffery
and Utter 2003). The fundamental basis of all obesity management is in life-style
changes that promote weight loss and prevent weight regain. The most important life-
style changes include decreased energy intake from the diet and increased energy
consumption by physical activity.
The basic methods to achieve a healthy weight reducing diet are: 1) to consume at
least 500 g of vegetables, fruits, and berries daily, 2) to consume whole grain bread,
grains, pasta, rice, and potatoes, 3) to control fat intake (not more than 30% of daily
energy intake), 4) to replace most saturated fats with unsaturated vegetable oils or soft
margarines, 5) to replace fatty meat products with beans, legumes, lentils, fish, poultry
or lean meat, 6) to prefer low-fat milk and dairy products, 7) to select foods low in sugar
and eat refined sugar sparingly, limiting the frequency of sugary drinks and sweets, and
8) to limit the use of alcohol which also includes energy. Foods low on energy density
may decrease the energy intake without affecting hunger and feeling of fullness (Rolls
2000). Most RCTs with diet interventions have used low-energy diet or hypoenergetic
diet containing 5.0-6.3 MJ of daily energy intake. This can be achieved by reducing fat
intake, reducing the size of food portions, or reducing both fat content and size of food
portions. Some studies have used a slightly different approach: low-energy diet was
achieved by reducing current total daily energy intake by 2.1-4.2 MJ. The interventions16
aiming at dietary changes have resulted in 3-11% weight loss in 4-36 months of follow-
up (Mulrow et al. 2000).
Most RCT’s with physical activity intervention have used 4.2-8.4 MJ of daily energy
consumption (Wing 1999). Physical activity (without other life-style changes) results in
minor weight loss. Combining physical activity to low-energy diet does not produce
clear increase in weight loss result. Physical activity seems to play a much more
important role in the prevention of weight regain after weight loss (Fogelholm and
Kukkonen-Harjula 2000). Observational studies have shown clear association between
exercise and success in weight loss maintenance, but the evidence from intervention
studies is modest. The authors conclude, “high physical activity is associated with
improved maintenance of body weight, but that the effects of a prescribed exercise
programme remain very limited”.
Behaviour modification or behaviour therapy includes the methods implementing
changes in diet and physical activity. The fundamental core of behaviour modification
includes stimulus control, self-monitoring, and cognitive restructuring (Brownell 1989).
Behaviour modification also includes information on healthy eating and physical
activity. Table 4 presents behaviour modification techniques. The readiness to change
behaviour is usually divided into different stages: pre-contemplation, contemplation,
preparation for action, and action (Prochaska et al. 1992). A person may shift between
stages, but obesity management is not meaningful before reaching the action stage.
Changing behaviour takes time. Modern weight loss programmes span 4 to 6 months
minimum. The communication between the therapist and the patient is motivational and
patient centred. This means that the therapist gives information and alternatives, but
the patient makes choices and decisions (Mustajoki 1998). After all, the patient
him/herself is responsible for the permanent life-style changes necessary for long-term
weight maintenance after the initial weight loss. There is no RCT comparing behaviour
modification methods to no treatment. Several studies show that combining diet
intervention to behaviour modification improves the weight loss result compared to
behaviour modification alone (Long et al. 1983, Wadden and Stunkard 1986, Wadden
et al. 1989, Jeffery et al. 1993, Wing et al. 1996).
2.3.2 Very-low-energy  diet
VLED includes less than 3.4 MJ of daily energy intake. This can be achieved by
specially developed commercial liquid or powdered diet formulas, which include at least
50 g protein, 10-80 g carbohydrates, 3 g essential fatty acids, vitamins, minerals and
trace elements in order to fulfil all essential nutritional requirements. VLED may be
used for 6-12 (up to 16) weeks as the only diet. The higher the baseline weight the
higher the weight loss rate. The weight loss rate tends to decrease towards the end of
the VLED-period (Mustajoki and Pekkarinen 2001).
In studies with VLED as the weight loss intervention, 8-16 weeks of this diet results in
15-21 kg of weight loss. Studies with longer follow-up after the VLED-period show large
variety: at 1-2 years, the mean weight loss has been 8.6-14.2 kg. (Wadden and17
Stunkard 1986, Wing et al. 1991, Wadden et al. 1994, Wing et al. 1994a, Ryttig et al.
1997, Torgerson et al. 1997). A meta-analysis (Anderson et al. 2001) on low- and very-
low-energy diets included 29 studies meeting the inclusion criteria: 1) studies were
conducted in the USA, 2) studies included a structured weight loss programme, 3)
studies provided long-term follow-up data ≥ 2 years. This meta-analysis showed that
VLED’s were associated with significantly better weight loss maintenance than
hypoenergetic diets. Weight loss was 7.1 kg (95%CI 6.1-8.1) and 2.0 kg (1.5-2.5) for
VLED and hypoenergetic diets, respectively. After VLED’s or weight loss of ≥ 20 kg
individuals maintained significantly more weight loss than after hypoenergetic diet or
weight loss <10 kg. In Finnish studies using VLED and behaviour modification, the
proportions of patients achieving >5% weight loss at two years has ranged from 38 to
54% (Pekkarinen et al. 1996, Fogelholm et al. 2000). At five years, the result was
better with VLED and behaviour modification than with VLED alone: 75% and 31% of
patients achieved >5% weight loss at 5-6 years after the weight loss programme,
respectively (Pekkarinen and Mustajoki 1997).
Table 4. Core elements of behaviour modification techniques (in Mustajoki 1998,
modified from Williamson and Perrin 1996, Wing 1997).
Stimulus control
Eating three regular meals daily
Slowing the pace of eating
Shopping for food according to a list, and not when hungry
Storing food out of sight
Separating eating from other activities (e.g. watching TV or reading)
Eating in the same place when at home
Self-monitoring
Keeping a food and exercise diary
Monitoring antecedent conditions for eating and exercise
Regular monitoring of body weight
Reinforcement
Rewarding changes in behaviour, not changes in weight
Social support
Selecting a support partner
Thanking the partner for his/her help
Making specific requests
Cognitive reconstructing
Avoiding dichotomic (black and white) thinking
Changing negative thoughts
Preparing beforehand for relapses
Table 5 presents the contraindications to VLED. Concomitant medication has to be
adjusted before the VLED-period. Possible weight loss induced changes in the
metabolism of a drug or the disease itself have to be considered. The dosage of drugs
for hyperglycaemia, hypertension, and dyslipidaemia may be reduced or discontiuned.
Warfarin dosage needs to be adjusted carefully with frequent monitoring of INR. The
dosage of drugs against some chronic diseases (e.g. drugs for angina pectoris,
asthma, epilepsy, depression, etc.) does not need tapering.18
Table 5. The absolute and relative contraindications to very-low-energy diet.
Modified from Mustajoki and Pekkarinen 2001.
Absolute Relative
BMI <25 kg/m
2 Age <16 or >65 years
Severe systemic or organ disease BMI 25-30 kg/m
2
e.g. recent myocardial or  Gout
cerebrovascular ischaemia,
major dysrythmias, severe
renal or hepatic disease,
systemic infection, malignancy
Type 1 diabetes
Pregnancy and lactation
Major eating disorder
Major psychiatric disease
2.3.3 Pharmacotherapy
Behaviour modification aiming at permanent changes in life-style with or without the
initial use of VLED produces clinically significant weight loss, but successful
maintenance of lost weight is the most important challenge of modern obesity
management. Attempts to improve behaviour modification techniques achieving better
weight loss maintenance are now supported by modern drug development. Currently
there are numerous weight loss drugs under investigation. A few of them have reached
clinical testing phase. Two of them are on the market currently in the European Union:
orlistat and sibutramine.
In clinical guidelines of obesity management, weight loss drugs are reserved for adult
patients with BMI >30 kg/m
2 or >27-28 kg/m
2 among patients with obesity related
comorbidity (Clinical Guidelines on the Identification, Evaluation, and Treatment of
Overweight and Obesity in Adults 1998, Mustajoki et al. 2002). Usually, a successful
2.5 kg weight loss with life-style changes is recommended before initiating drug
therapy. Drug treatment must be implemented with behaviour modification and dietary
advice; most RCT’s with weight loss drugs include a comprehensive programme
implementing behavioural strategies - at least low-energy (fat) diet and increased
physical activity. If weight loss during the first three months on the drug doesn’t exceed
5% of baseline weight, there is no need to continue drug treatment.
Orlistat is a gastrointestinal lipase inhibitor that inhibits part of the absorption of fat in
the intestinal tract. About 30% of the ingested fat pass through the bowel and are
excreted in the faeces (Zhi et al. 1994). This leads to reduced energy intake. The
evidence from RCT’s shows that orlistat enhances weight loss and prevents
subsequent weight regain among obese individuals. (Hollander et al. 1998, Sjöström et
al. 1998, Davidson et al. 1999, Hauptman et al. 2000, Heymsfield et al. 2000,
Lindgarde 2000, Rössner et al. 2000). The adverse effects of orlistat are due to its
mechanism of action. The most commonly reported adverse effects include fatty/oily19
stools, faecal urgency, and oily spotting. These adverse effects usually appear early
during treatment, diminish over time, and rarely result in discontinuation of treatment.
Sibutramine is an adrenaline and noradrenaline reuptake inhibitor that works in the
central nervous system by increasing satiety (Stock 1997). Sibutramine enhances
weight loss and prevents subsequent weight regain (Apfelbaum et al. 1999, James et
al 2000, McMahon et al. 2000, Smith et al. 2001). Sibutramine slightly but significantly
increases both blood pressure (Kim et al. 2003) and heart rate; therefore it is not
recommended for hypertensive subjects and subjects with coronary heart disease. The
most common adverse effects of sibutramine include dry mouth, anorexia, and
insomnia.
In a systematic review including 11 orlistat and 3 sibutramine studies with follow-up
periods of at least one year showed that compared to placebo, orlistat produced 2.7 kg
(95%CI: 2.3-3.1) or 2.9% (2.3-4.3) greater reduction in weight and sibutramine
produced 4.3 kg (3.6-4.9) or 4.6% (3.8-5.4) greater reduction in weight (Padwal et al.
2003). Not included in this review is the XENDOS-study on orlistat with 4-year follow-
up showing significantly greater weight loss with orlistat than placebo (5.8 vs. 3.0 kg)
(Torgerson et al. 2004).
2.3.4 Surgery
Several surgical techniques resulting in malabsorptive or restrictive effects on food
intake have been developed in order to improve weight loss and weight maintenance
among obese patients. The techniques include intestinal, gastric, or combined
operations. According to a review (Sjöström 2000), the surgical methods of choice are
gastric bypass (GBP), vertical banded gastroplasty (VBG), and gastric banding (GB)
presented in figure 1.
Figure 1. Procedures of weight loss surgery. A) Vertical banded gastroplasty, B)
Gastric banding, C) Gastric bypass.
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Several long-term studies have shown, that gastric bypass results in the greatest
weight loss. When compared to vertical banded gastroplasty, the weight loss in GBP
and VBG groups was 35 vs. 30% after 2.5 years (Fobi and Fleming 1986), 32 vs. 20%
after 3 years (Sugerman et al. 1987), 34 vs. 28% after 3 years (Hall et al. 1990), 32 vs.
22% after 2 years (Sjöström et al. 1999), and 24 vs. 16% after 8 years (Sjöström et al.
2000). When compared to GB, the advantage for GBP is even greater (Sjöström et al.
2000). GBP is technically more demanding and results in iron and vitamin B12
insufficiency, which must be treated. Also endoscopic examination is more difficult after
GBP. Gastric bypass should be reserved for individuals with a BMI ≥ 40 kg/m
2 (Sjöström
2000).
Vertical banded gastroplasty and gastric banding give similar weight reductions.
According to the experience from the Swedish Obese Subjects (SOS) –study with 8
years of follow-up, the body weight of GB and VBG patients was 120.2 and 120.6 kg at
baseline, 94.6 and 93.0 kg at 2 years, and 101.6 and 101.5 kg at 8 years, respectively
(Sjöström et al. 2000). The original form of banding should not be used because of the
increased need for revisions. Variable banding seems to have a place in obesity
surgery, although a randomised controlled trial of its efficacy and safety is urgently
needed. Vertical banded gastroplasty and variable gastric banding may be effectively
and safely used among less severely obese subjects with BMI 35-45 kg/m
2. The 8-year
follow-up study shows a weight loss of 20.1± 15.7 kg in the surgically treated group
compared to the 0.7± 12.0 kg weight increase in the control group (Sjöström et al.
2000).
Only one study has compared surgically achieved weight loss to non-surgical weight
loss. This non-randomised study compared GBP and VLED during 2 to 6 years of
follow-up. The BMI for GBP and VLED groups, respectively, was 49.3 and 41.2 kg/m
2
at baseline, 31.8 and 32.1 kg/m
2 at 2 years, and 33.7 and 38.5 kg/m
2 at 6 years. 34.5%
in GBP and 19.7% in VLED completed the follow-up (Martin et al. 1995).
2.4  Consequences of intentional weight loss
2.4.1  Cardiovascular risk factors and type 2 diabetes
Although life-style changes lead to more modest weight loss than surgical methods,
numerous RCTs show that 5-10% of intentional weight loss is enough to prevent
obesity related metabolic complications. Weight loss of this magnitude in high-risk
obese populations reduces the risk of hypertension (Stamler et al. 1989, Stevens et al.
2001) and type 2 diabetes (Tuomilehto et al. 2001, Diabetes Prevention Program
Research Group 2002, Torgerson et al. 2004).
A systematic review on 18 randomised controlled weight loss trials with 2 611
hypertensive subjects showed that weight loss of 3-9% reduces both systolic and
diastolic blood pressure by 3 mmHg (Mulrow et al. 2000). Weight loss also reduces the21
needed dose of antihypertensive agents. This analysis did not report any estimation on
how much blood pressure decreases per lost kilogram of body weight.
Generally, weight loss leads to increase in serum HDL-cholesterol and decrease in
serum triglycerides (Stefanick et al. 1998, Yu-Poth et al. 1999, Metz et al. 2000).
During active weight loss with hypoenergetic diet HDL-cholesterol may decrease, but
during successful weight maintenance its concentration increases above the baseline
level (Dattilo and Kris-Etherton 1992, Noakes and Clifton 2000). A meta-analysis (Yu-
Poth et al. 1999) of dietary interventions showed that for every 1 kg weight reduction
triglycerides decreased by 0.011 mmol/l and HDL-cholesterol increased by 0.011
mmol/l. Weight loss was not associated with changes in LDL-cholesterol, but for every
1% decrease in energy consumed as dietary saturated fatty acid LDL-cholesterol
decreased by 0.05 mmol/l. The mean weight loss in the included studies was 3.38 kg;
the follow-up ranged from 3 weeks to 4 years.
Among obese type 2 diabetics, intentional weight loss improves glycaemic control and
reduces the need for hypoglycaemic agents (Kaplan et al. 1987, Laitinen et al. 1993,
Pascale et al. 1995, Metz et al. 2000). Subjects with type 2 diabetes have lost less
weight than non-diabetic subjects in some (Henry et al. 1986, Wing et al. 1987, Khan et
al. 2000, O’Meara et al. 2004), but not all (Guare et al. 1995) studies. A number of
factors may confound attempts to reduce weight among type 2 diabetics: comorbidities
affecting body weight, therapies affecting body weight (Van Gaal and Peiffer 2001),
and possible previous attempts to lose weight before developing type 2 diabetes,
thereby reducing their success in further attempts (Turner et al. 1996).
The use of VLED among obese patients with type 2 diabetes leads to marked weight
loss and improvement in glycaemic control and hyperglycaemic symptoms. A meta-
analysis of nine studies using VLED for 4-6 weeks among obese type 2 diabetes
patients concluded, that the weight loss was about 10% and the decrease in fasting
plasma glucose value was about ≤ 50% of initial values (Anderson et al. 2003). Larger
weight losses were associated with larger improvements in glycaemic control.
Subsequently, the use of insulin or oral anti-diabetic medications can be decreased or
discontinued – at least transiently (Paisey et al. 1998). The weight loss with VLED also
improves serum lipid profiles (Osterman et al. 1992, Pekkarinen et al. 1998) and blood
pressure (Pekkarinen et al. 1998, Laaksonen et al. 2003b).
It is still unclear how much of these improvements in cardiovascular risk factors can be
accounted for the energy restriction alone. The studies with longer follow-up have
contradicting results. Despite of some weight regain during the first follow-up year,
sustained improvement in glycaemic control has been reported, though control tends to
deteriorate during longer follow-up (Dhindsa et al. 2003). In one randomised trial, the
weight loss with VLED led to larger improvement in glycaemic control and longer drug-
free period compared to the weight loss with low-energy-diet (Wing et al. 1994b). Also
the glycaemic control was better after VLED despite no difference in weight loss at 12
months. A Finnish study among obese patients with the metabolic syndrome showed
that blood pressure decreased during the VLED (-9.0/-4.6 mmHg), but rose back to22
baseline levels despite successful weight loss maintenance at the end of 12-month
follow-up (Laaksonen et al. 2003b). Another study reported that during VLED the blood
pressure decreased markedly and at one-year follow-up, systolic and diastolic blood
pressures were still at a lower level compared to baseline (mean change –4.1 and –3.0
mmHg, respectively). The mean weight loss at one year was 10.7 kg (Pekkarinen et al.
1998).
The weight loss associated with orlistat improves the risk factors of cardiovascular
diseases. Orlistat seems to have an independent effect in reducing LDL-cholesterol
(Sjöström et al. 1998). Among obese type 2 diabetics orlistat enhances weight loss
(table 6), which is associated with better glycaemic control and less need for oral
hypoglycaemic agents compared to the placebo group (Hollander et al. 1998, Hanefeld
et al 2002, Kelley et al. 2002, Miles et al. 2002, Halpern et al. 2003). In the XENDOS-
study after 4 years of treatment, the cumulative incidence of diabetes was 9.0% with
placebo and 6.2% with orlistat, corresponding to a risk reduction of 37.3% (Torgerson
et al. 2004). At baseline, 21% of patients had impaired glucose tolerance. In this group,
the cumulative incidence of diabetes was 14.2% vs. 8.3% among those with normal
glucose tolerance at baseline.
The weight loss associated with sibutramine treatment improves blood lipid profile (Van
Gaal et al. 1998, Apfelbaum et al. 1999, Bray et al. 1999, James et al. 2000). The
evidence from RCT’s on sibutramine among obese subject with type 2 diabetes is
collected in table 6: only one out of four placebo-controlled trials showed significant
improvement in glycaemic control with sibutramine despite of the superior weight loss.
The surgical treatment of obesity leads to markedly reduced weight that is maintained
for years after the operation. This weight loss is associated with clear improvements in
obesity-related metabolic disturbances. Weight loss surgery leads to withdrawal of
diabetic medication in about 60% or more of the patients, and reductions in medication
for many others (Pinkney and Kerrigan 2004).
In the SOS-study at the two-year follow-up, the weight loss in the surgically treated
group resulted in dramatic reductions in the incidence of hypertension, diabetes,
hyperinsulinaemia, hypertriclyceridaemia, and low HDL-cholesterol (Sjöström et al.
1999). The incidence of hypercholesterolaemia was not affected by weight loss. Up to
eight years, the incidence of diabetes was five times lower than in the control group
(3.6% and 18.5% in the surgical and control groups, respectively), whereas the
difference between the two groups with respect to the incidence of hypertension was
no longer evident (Sjöström et al. 2000). It seems, that marked weight loss induced by
surgical techniques improves the risk factor profile for cardiovascular diseases, but
some risk factors may relapse during longer follow-up.23
Table 6. Randomised clinical trials on sibutramine or orlistat with at least 6 months of
follow-up among obese subjects with type 2 diabetes.
Mean change from baseline
Reference
Diabetes
medication
Treatment
arms N(men)
Baseline
BMI (kg/m
2)
Age (y) Drop-
out (%) Weight(kg) FPG(mmol/l) HbA1c(%)
SIBUTRAMINE
Fujioka None/SU/M S 20 mg 89(51) 34.1 54 33 -4.3*** 0.6 0.2
et al. 2000 P 86(42) 33.8 55 29 -0.4 1.0 0.3
Gokcel SU/M/G S 10 mg 30(0) 39.3 47 3 -9.6*** -125(mg/dl)*** -2.7***
et al. 2001 P 30(0) 37.4 49 17 0.9 -16(mg/dl) -0.5
Serrano-Rios SU S 15 mg 69(26) NA 53 23 -4.5*** -0.8 -0.8
et al. 2002 P 65(17) NA 54 12 -1.7 -0.3 -0.7
McNulty M S 20 mg 62(27) 37.5 48 21 -8.0*** -0.1 -0.3
et al. 2003 S 15 mg 68(36) 36.3 49 28 -5.5*** -0.3 -0.6
P 64(22) 36.2 51 28 -0.2 0.2 -0.2
ORLISTAT
Hollander SU O 162(79) 34.5 55 15 -6.2*** -1.0*** -0.3***
et al. 1998 P 159(85) 34.0 55 27 -4.3 -0.6 0.2
Hanefeld and None/SU O 189(90) 34.5 57 33 -5.4** -1.6** -0.9***
Sachse 2002 P 180(91) 33.7 56 29 -3.6 -0.7 -0.4
Kelley Insulin O 266(116) 35.8 58 49 -3.9*** -1.6* -0.6**
et al. 2002 P 269(118) 35.6 58 52 -1.3 -1.1 -0.3
Miles M O 250(132) 35.6 53 44 -4.7*** -2.0** -0.8*
et al. 2002 P 254(130) 35.2 54 35 -1.8 -0.7 -0.4
Halpern None O 164(47) 34.6 51 15 -4.7*** -1.0* -0.6*
et al. 2003 P 174(57) 34.5 51 19 -3.0 -0.0 -0.2
FPG=fasting plasma glucose, G=glipizide, HbA1c=glycosylated haemoglobin,
M=metformin, NA=not available, O=orlistat 120 mg x 3 daily, P=placebo,
S=sibturamine, SU=sulphonylurea, *=p≤ 0.05, **=p≤ 0.01, ***=p≤ 0.001 compared to
placebo24
2.4.2  Testosterone and sexual functions
The studies on the effect of intentional weight loss on testosterone level have
contradicting results, with some studies showing increase (Stanik et al. 1981, Pasquali
et al. 1988, Strain et al. 1988, Bastounis et al. 1998, Pritchard et al. 1999, Niskanen et
a. 2004), other studies showing no change (Hoffer et al. 1986, Leenen et al. 1994,
Kraemer et al. 1999), and one small study showing decrease in testosterone (Klibanski
et al. 1981). One study with surgically induced weight loss reported improvement in
sexual functions, but serum testosterone level was not examined in this study (Larsen
1990). Some studies have reported improvement in marriage after weight loss surgery
(Rand et al. 1982, Globe et al. 1986), but some have not (Neill et al. 1978). A more
recent study among the patients’ partners reported that 59% of partners had
experienced improvement in partnership and 45% improvement in sexual relationship
after the patients had laparoscopic gastric banding (Kinzl et al. 2003). Among poorly
controlled diabetics, weight loss and related improvement in glycaemic control have
been associated with improved sexual functions (Fairburn et al. 1982).
2.4.3  Symptoms and findings of chronic conditions
In addition to metabolic benefits, intentional weight loss also reduces symptoms and
improves findings in a number of obesity-related chronic conditions. Uncontrolled
intervention trials show that weight loss is associated with less apnoea periods and
better quality of sleep among obese subjects with obstructive sleep apnoea (Smith et
al. 1985, Kansanen et al. 1998, Lojander et al. 1998). A RCT and a surgical study
documented improved respiratory function, fewer symptoms, and lower doses of
medication with weight loss among obese subjects with asthma (Dixon et al. 1999,
Stenius-Aarniala et al. 2000). Studies among obese subjects with osteoarthritis
reported less pain and better physical functioning after weight loss (Huang et al. 2000,
Martin et al. 2001). Weight reduction has also improved symptoms and findings in
coronary angiography among obese subjects with coronary heart disease (Ornish et al.
1990, Singh et al. 1992).
2.4.4  Depression and anxiety
The effects of weight loss on psychopathology are poorly studied: there are no well-
designed studies evaluating the effects of weight loss on depression or anxiety. The
effects of weight loss on stigmatisation, discrimination, etc. are largely unknown. The
surgical weight loss studies provide the best evidence to date. The symptoms of
depression and anxiety have been reversed by the marked weight loss achieved by
surgical techniques (Karlsson et al. 1998), therefore researches say that psychological
morbidity associated to obesity is likely to be a consequence rather than the cause of
obesity. The effects of life-style interventions remain to be evaluated in future studies.25
2.4.5 Mortality
Weight loss can be intentional (conscious attempt to lose weight) or unintentional (a
result of underlying disease). In the past, this confounding was poorly controlled for and
due to these methodological problems weight loss was not associated with decreased
mortality in the earlier observational studies. In recent studies, intentional weight loss
has been associated with less mortality in high-risk obese populations (Williamson et
al. 1995, Williamson et al. 2000). The evidence from intervention studies is still missing.
The somewhat conflicting results in the studies assessing weight change and mortality
have to be weighed against the methodologically sound evidence from RCTs showing
the benefits of intentional weight loss: improvement in obesity-related metabolic
complications and reduced findings and symptoms in several obesity-related chronic
conditions.
2.4.6 Health-care  costs
There are no economical evaluations on weight loss interventions based on life-style
changes and behaviour modification. However, the effect of weight loss on health-care
costs has been estimated in weight loss drug trials. The cost utility of orlistat treatment
was estimated as GB£ 45 881 per quality-adjusted life year (O’Meara et al. 2001). The
use of orlistat in overweight and obese patients with type 2 diabetes results in
increased event-free life expectancy of 0.13 years over an 11-year period and the cost-
effectiveness radio was US$ 8 327 per event-free life-year gained (Maetzel et al.
2003). In another analysis, the cost-effectiveness was estimated at €3 462 per life-year
gained for obese diabetic patients with hypertension and hypercholesterolaemia
(Lamotte et al. 2002). The cost per quality-adjusted life year for sibutramine was
estimated as GB£ 10 500 (O’Meara et al. 2002).
For comparison, the cost per life year gained is GB£ 26 000-31 000 for implantable
defibrillators for arrythmias, GB£ 7 000-24 000 for taxanes for breast cancer (Raftery
2001), and GB£ 20 000 for statins in primary prevention (Caro et al. 1997).
The SOS-study compared differences in sick leave and disability pension during over 5
years of follow-up after entering either surgical or conventional treatment (Narbro et al.
1999). Compared with weight stable control group, the surgical group had 35% more
days of sick leave during the first year after operation, but 10-14% fewer days during 2
to 3 years of follow-up. The number of days with disability pension was lower in
surgically treated group during 3 to 4 years of follow-up. In the same study, the average
yearly medication costs during a six-year follow-up were US$ 185 in surgically treated
patients (weight change –16%) and US$ 190 in conventionally treated patients with no
significant difference between these groups (Narbro et al. 2002). The surgical group
had lower costs for diabetes medication and cardiovascular disease medication, but
higher costs for gastrointestinal tract disorders, anaemia, and vitamin deficiency
medications. At six years, there were no differences between the surgically and
conventionally treated groups in the number of hospital days or hospitalisation costs
(Ågren et al. 2002). However, a systematic review suggested that surgery compared to26
non-surgical management was cost effective at GB£ 11 000 per quality-adjusted life
year (Clegg et al. 2003).
2.4.7 Adverse  effects
Weight loss programmes with behaviour modification have not increased the risk of
eating disorders. On the contrary, the scores of questionnaires measuring disordered
eating have decreased during and after structured weight loss interventions
(Pekkarinen et al. 1996, National Task Force 2000b).
The obese have higher bone density in weight baring bones (femur and spine) and
other bones (e.g. radius) (Aloia et al. 1995, Slemenda 1995). During weight loss the
mineral density of bone may decrease (Salamone et al. 1999, Fogelholm et al. 2000).
No studies have examined the effects of maintained weight loss on fracture risk later in
life.
The risk of gall stones increases with rapid weight loss regardless of the method. The
incidence of new gallstones has been 0-26%. Most of the new gallstones are
asymptomatic and resolve spontaneously (Everhart 1993). A weight loss rate
exceeding 1.5 kg/week seems to increase the risk dramatically (Weinsier et al. 1995).
Many of these studies have used daily energy intake ≈ 500 kcal and very low fat content
≈ 1 g/day. Addition of fat to the diet stimulates emptying of the gall bladder and prevents
the formation of gallstones (Festi et al. 1998). The incidence of symptomatic gallstones
with modern VLEDs that include more fat is not known.
VLEDs have been in clinical use over 20 years and modern formulas are safe but not
free form adverse effects (Henry and Gumbiner 1991, Mustajoki and Pekkarinen 2001).
The first 2-3 days are usually most difficult with hunger, fatigue, dizziness, and
headache, but these symptoms usually diminish after a few days with adequate
rehydration. Later, many experience dry skin, bad smell of breath, and cold intolerance.
Fairly common are also orthostatic hypotension, myalgias, arthralgias, and menstrual
alterations. About 10% of users experience significant hair loss, which usually becomes
manifest after the VLED-period and is not permanent. Constipation can be avoided by
the use of low energy vegetables or fibre preparations. Transaminases may rise during
VLED, but after VLED (in the weight maintenance phase) they usually are lower than
before therapy. Especially patients with a history of gout attacks may develop an acute
attack as serum uric acid increases during the first weeks on VLED. These attacks can
be prevented by allopurinol in high-risk individuals (Shiffman et al. 1995).
The surgical complications in the SOS-study (peri- and postoperative complications for
1164 patients followed for 4 years) have been published (Sjöström 2000). The
perioperative death rate was 0.21% (February 2000, 1870 operated patients). During
the primary hospital stay, there were the following complications: bleeding (0.5%),
embolus and/or thrombosis (0.8%), wound complications (1.8%), deep infections
(2.1%), pulmonary (6.1%), and other complications (4.8%). Altogether, 13% of patients
had complications. 2.2% of patients had to be re-operated due to these complications.27
During the 4-year follow-up 12% of patients underwent additional operations, usually
owing to poor weight loss or vomiting and other side effects (e.g. ventral hernia,
gallbladder disease, intestinal obstruction, surplus of skin). When needed, GP or VBG
was usually converted to GPB (Sjöström 2000).
2.5  Health-related quality of life
2.5.1  Definition of concepts
Traditionally medical research has focused its attention on morbidity and mortality.
Typical indices of health status have included biochemical data (e.g. blood glucose),
routinely collected statistics on health service use (e.g. doctor visits), morbidity (e.g.
diabetes), and behavioural data (e.g. smoking). The aim of clinical interventions has
been to cure disease and to postpone death. However, if medical care were to be
judged on the criteria of increasing longevity, only a small fraction of care delivered
would meet the required standard. The paradox of health is that interventions may
reduce morbidity and/or mortality, but do not necessarily improve the quality of the
patient’s everyday life (relieve symptoms, improve mental health, restore functioning, or
reduce pain and discomfort).
The World Health Organisation has declared health to be ”a state of complete physical,
mental, and social well-being, and not merely the absence of disease or infirmity”
(WHO 1948). This was one of the earliest statements recognising and stressing the
importance of the three dimensions – physical, mental, and social – in the context of
health and disease. Later it was emphasised that in addition to dimensionality, health
can range from negative states of disease to more positive states of well-being (Ware
1987). "The terms ‘quality of life’ and, more specifically, ‘health-related quality of life’
refer to the physical, mental, and social aspects of health, seen as distinct areas that
are influenced by a person's experiences, beliefs, expectations, and perceptions"
(Testa and Simonson 1996). Thus health-related quality of life reflects an individual’s
subjective evaluation and reaction to health or disease.
Though there is no uniform definition for quality of life, there is general agreement that
it can include at least the dimensions of general health, physical functioning, physical
symptoms, emotional functioning, cognitive functioning, role functioning, social well-
being and functioning, sexual functioning, and existential issues. What is finally
included in a study on HRQL depends on the researches’ interests, the disease, the
study population, the intervention, and the available instruments.
Unifying and non-controversial in all approaches to HRQL is that these dimensions can
be assessed only by subjective measures and that they should be evaluated by asking
the patient. The patient is asked what he/she can do (functioning) and what he/she
feels (well-being). It is clear, that independent assessments by healthcare
professionals or patients’ relatives would be different from the responses obtained from
the patient him/herself (Addington-Hall and Kalra 2001).28
Medical research has yielded knowledge on the obesity-related health risks and on the
health benefits of intentional weight loss. Much less is known about the impact of
obesity and weight loss on HRQL. Obesity is considered a chronic and mostly
incurable condition. The primary goals of obesity treatment are some degree of
maintained weight loss, control of obesity-related chronic conditions and their
symptoms, and minimal adverse effects of weight loss or treatment. The obvious
measure of treatment efficacy should be the effect it has on the patients’ functional
status and well-being. HRQL assessments are of use to the clinicians, researches,
administrators, and policy makers. Information on quality of life may influence the
development of clinical pathways, service provision, health care expenditures, and
public health policy.
2.5.2 Instrument  development
A large number of instruments have been developed in an attempt to quantify HRQL.
The definition of HRQL varies, therefore different instruments use different definitions
with different questions. When deciding on which measure to use, it should be
assessed whether the questions in the instrument are relevant to the study; the type of
scoring that the instrument is based on; the reliability, validity, and sensitivity of the
instrument; and the appropriateness and the acceptability of the instrument for the
study population (Higginson and Carr 2001).
The development of an instrument involves item generation, item scaling, and item
aggregation into domains. Each question on the HRQL instrument is an expression in
words for an item. The response to an item is graded. For example, the responses to
an item ‘I expect my health to get worse’ may be graded as ‘definitely true’, ‘mostly
true’, ‘don’t know’, ‘mostly false’, and ‘definitely false’ representing a scale of numbers
from 0 to 4. Usually, this working score is standardised to range of 0 to 100 and called
the scale score. Often HRQL concepts are complex and require several questions.
These multiple items can then be combined together to produce a multi-item scale that
represent a specific domain. For example, several questions on the ability to perform
tasks requiring mobility are combined to a domain called ‘physical functioning’. After
constructing the questionnaire, it has to demonstrate validity, reliability, sensitivity, and
acceptability.
Validity is concerned with whether the indicator actually measures the underlying
attribute or not. The following validity criteria should be met: 1) content validity (Do the
components cover all aspects of the attribute?), 2) face validity (Do the components
measure the variables they claim to measure?), 3) criterion validity (Can the variable
be measured with accuracy?), and 4) construct validity (Does the measurement
correlate to other measures of related variables? Does it correlate to measures of other
variables?).
Reliability is concerned with whether the measure consistently produces the same
results, particularly when applied to the same subjects at different time periods when29
there is no evidence of change. There are several methods to test reliability: 1) internal
consistency (Do the components come from the same conceptual domain?), 2) test-
retest reliability (Do the responses to a measure differ when administered to the same
population on two occasions?), and 3) intra- and inter-rater agreements.
Sensitivity is the ability to distinguish between individuals and groups in different health
states (discriminatory power) and to detect changes in individuals or groups over time
(responsiveness to change in health status). Acceptability includes the time needed to
complete the questionnaire, the physical and mental ability of the target population, the
rate of refusal to complete the questionnaire, and the percentage of missing items.
The majority of questionnaires have been developed in Anglo-American countries.
Cross-cultural adaptation is necessary to make the questionnaires available in different
languages. Linguistic translation and validation ensures that the same meaning of the
original concepts exists in all translations. A questionnaire is adapted to a new
language by a methodology that uses forward translations, backward translations,
international harmonisation, and debriefing interviews with subjects from the target
population. The translated instrument should be validated for psychometric properties
and normed using representative samples of target or general population (Bullinger et
al. 1998).
The concept of minimal clinically important difference (MCID) has been proposed to
refer to the smallest difference in score that is considered to be worthwhile or
important. The purpose of MCID is to aid interpretation of HRQL questionnaire scoring.
2.5.3  Global questions and generic instruments
A global question, such as “Do you consider you health to be excellent, good, fair, or
poor?” may be subject to a wide variety of interpretations and does not provide
information on different dimensions of health. Often a global question is used for overall
quality of life, overall health-related quality of life, overall health status, or similar
concepts that are assumed to be broadly understood by the majority of respondents. A
single question is easy to administer and has proven valuable in large population
studies, but can also be used in clinical trials.
The broader measures of HRQL are called generic instruments. These measures
encompass the dimensions of physical, mental, and social health. These are not
designed to assess HRQL relative to a particular medical condition, but rather provide
a generalised assessment. They can be used to make comparisons with other
conditions and the general population. A generic instrument can also be used to
measure outcome in clinical studies. The advantage of multi-item scaling is that a
composite score from several questions tapping a particular concept is more reliable.
High reliability increases the probability of reaching good validity. Another advantage is
that the score is possible to calculate even if some answers are missing (the half-scale
option: the score can be calculated if at least half of the questions are answered)
(Nunnally and Bernstein 1994).30
The most widely used SF-36/RAND-36 covers separate scales on the physical HRQL:
physical functioning, physical role functioning, bodily pain, and general health; the
mental HRQL: mental health, emotional role functioning, vitality and social functioning.
Each scale has a score range from 0 (maximal impairment) to 100 (no impairment).
Physical and mental health summary scores can be derived from these eight scales.
The SF-36/RAND-36 also includes a global assessment of health-change since last
year (5-point scale from much worse to much better).
Other widely used generic instruments, that are designed to yield scores on multiple
aspects of HRQL, are the Sickness Impact Profile and the Nottingham Health Profile
(table 7).
Table 7. Examples of generic health status/quality of life questionnaires.
Domain SF-36 SIP NHP
Pain + - +
Energy/tiredness + + +
Sleep - + +
Physical functioning/mobility + + +
Daily living activities + + +
Social interactions + + +
Leisure activities + + -
Relationships - + -
Sexual functioning - - -
Work + + -
Emotional functioning + + +
Dependence/independence - + +
Self perception/body image - - -
Perceptions of the future - - -
+ =included, - =not included, SF-36=SF-36 Health Survey, SIP=Sickness Impact
Profile, NHP=Nottingham Health Profile
2.5.4 Obesity-specific  questionnaires
Generic instruments have an important constraint, as they are unable to identify
condition- or disease-specific aspects that are essential for the evaluation of outcome.
In addition to disease-specific questionnaires, the HRQL instruments can be specific to
a population (e.g. elderly), a clinical problem (e.g. pain), or a therapy (e.g.
chemotherapy). Generic measures will always require supplementation with disease-
specific measures in order to detect important clinical changes. Measures developed
for specific diseases or conditions are probably more sensitive and therefore more
relevant for practising clinicians. Disease-specific instruments also include the
questions most relevant to the patients.31
Several obesity-specific questionnaires have been developed (table 8). They each
have their strengths and weaknesses. The Impact of Weight on Quality of Life (IWQOL)
was presented in 1995, and it comprises 74 items and eight domains (Kolotkin et al.
1995). The IWQOL has been validated, but the sample used was homogenous and the
questionnaire may be unreliable when the test-retest interval exceeds one day
(Kolotkin et al. 1997). Later the IWQOL was replaced by the shorter IWQOL-Lite, which
includes 31 items and five scale constructs: physical function, self-esteem, sexual life,
public distress, and work (Kolotkin et al. 2001a). Separate and heterogeneous samples
were used to develop and validate IWQOL-Lite. The scale structure was verified with a
confirmatory factor analysis. The IWQOL-Lite is currently available in at least 14
languages, also in Finnish.
Another obesity-specific questionnaire, the Lewin-TAG, is an instrument in which two
thirds of the questions were derived from a previously validated HRQL instrument and
one third were new obesity-specific questions. The survey's strength is that it has
internally consistent scales and there is support for construct validity (Mathias et al.
1997). Some scales showed weak test-retest reliability and displayed instability in the
weight stable group. The Lewin-TAG is also quite lengthy which limits its use. The
OSQOL is brief with eleven questions (Le Pen et al. 1998). It was developed in a large
community sample in France. The OSQOL is able to differentiate obese and nonobese
populations on physical measures, but not on psychological and social measures.
Other weaknesses are that it has not been tested for test-retest reliability or internal
consistency of scales. There are no publications of the OSQOL on obese patients in
treatment.
Like the OSQOL, the ORWELL97 correlated physical symptoms but not psychosocial
effects to obesity (Mannucchi et al. 1999). The questionnaire is validated, and its total
score is internally consistent and shows good test-retest reliability. It is also relatively
short and therefore easy to administer. The OAS-SF was developed to measure
distress in morbid obesity and the impact of weight loss surgery on psychological
functioning. It is limited to measuring psychological distress only and quite a number of
items demonstrate poor psychometric properties (Butler et al. 1999). However, the total
score is internally consistent and shows good test-retest properties. The BAROS has
been used to compare the outcomes of different weight loss surgical procedures (Hell
et al. 2000). It is very simple to use, available in different languages, but it has not been
validated.
The Obesity Coping (OC) and Obesity Distress (OD) questionnaires developed as part
of the SOS QoL were found psychometrically valid and reliable in the SOS intervention
study (Rydén et al. 2001). The Obesity and Weight Loss Quality of Life (OWLQOL) with
41 items and the Weight-Related Symptom Measure (WRSM) with 20 items were
introduced in 2002 (Niero et al. 2002). After psychometric studies, the OWLQOL was
reduced to include 17 items. The questionnaires are brief, valid, reproducible, and
responsive in evaluating obesity and weight loss (Patrick et al. 2004). The OWLQOL
discriminated between genders, presence of disability days, levels of BMI, and levels of
symptom bothersomness.32
 Table 8. Obesity-specific questionnaires.
Reference Instrument
name
Items Country Domains
Sullivan
et al. 1993,
Karlsson
et al. 2003
Obesity-related
psychosocial
problems
(OP)
8 Sweden Obesity-related
psychosocial
problems
Kolotkin
et al. 1995,
1997, 2001a
Impact of weight
on quality of life –
Lite
(IWQOL-Lite)
31 USA Physical function
Self-esteem
Sexual life
Public distress
Work
Mathias
et al. 1997
Lewin –technology
assessment group
(Lewin-TAG)
55 USA General health
Comparative
health
Overweight
distress
Depression
Self-regard
Physical
Appearance
Health-state
Preference
Le Pen
et al. 1998
Obesity specific
quality of life
(OSQOL)
11 France Physical state
Vitality/desire to do
things
Relations
with other people
Psychological
state
Oria and
Moorehead
1998
Bariatric analysis
and reporting
outcome system
(BAROS)
7 USA Weight loss
Medical conditions
Self-esteem
Physical
Social
Labour
Sexual
Mannucci
et al. 1999
Obesity-related
well-being scale
(ORWELL97)
18 Italy Psychological
status/
Social adjustment
Physical
symptoms
Butler
et al. 1999
Obesity
adjustment survey
– short form
(OAS-SF)
20 Canada Overall obesity adjustment/
psychological distress
Ryden
et al. 2001
Obesity Coping
(OC)
16 Sweden Social trust
Fighting spirit
Wishful thinking
Obesity Distress
(OD)
13 Intrusion
Helplessness
Niero
et al. 2002,
Patrick
et al. 2004
Obesity and
Weight Loss
Quality of Life
(OWLQOL)
17 USA Feelings and beliefs related to obesity
and weight loss
Weight-Related
Symptom Measure
(WRSM)
20 USA Symptoms associated with obesity and
weight loss33
The Obesity-related psychosocial problems scale (OP scale), which measures obesity-
related psychosocial problems in everyday situations, has showed sound psychometric
properties (Karlsson et al. 2003). The OP scale is available in Finnish.
2.6  Obesity, weight loss, and health-related quality of life
2.6.1  Population based observational studies
Since 1994 several large population based cross-sectional and longitudinal studies
have examined the association between body weight and HRQL (table 9). All the
studies have been conducted either in Western Europe, Australia, or the USA. Those
methodologically sound studies include population samples of considerable size,
comprise subjects across a broad range of BMI, and use either global questions or
well-known and validated generic HRQL questionnaires.
The SF-36 measured HRQL in most studies. The most consistent finding has been the
association between obesity and poor physical functioning (figure 2). Mental scales
have not clearly been associated with obesity in all studies (Han et al. 1998, Le Pen et
al. 1998). Women with BMI 17-25 kg/m
2 had the highest scores on physical domains
and with 18.5-25 kg/m
2 the highest scores on mental domains. (Brown et al. 2000). An
English study showed that physical functioning, but not mental health was impaired
with increasing BMI (Doll et al. 2000). Subjects with chronic illnesses (more than 40%
of the sample) other than obesity had impairments both in physical functioning and
mental health, and both of these dimensions were most adversely affected in subjects
with both obesity and other chronic illnesses.
The Nurses’ Health Study measured changes in SF-36 scores and self-reported weight
over a four-year period from 1992 to 1996 (Fine et al. 1999). Weight gain was
associated with decreased physical functioning and vitality, and increased bodily pain
regardless of baseline weight. Weight loss was associated with improvements in these
same domains of HRQL.
Several studies have used global questions to study the association between weight
and health-related quality of life. A J-shaped association between self-rated health and
BMI has been evident in a couple of studies (Manderbacka et al. 1999, Ford et al.
2001), but others have reported linear association (Okosun et al. 2001). The number of
poor physical health days has been significantly greater among the obese compared
with the non-obese (Goins et al. 2003). In America, compared to normal weight (BMI
18.5-25) subjects, the odds ratios for poor or fair self-rated health were 1.12 (95%CI
1.04-1.20) with BMI 25-30, 1.65 (1.50-1.81) with BMI 30-35, 2.58 (2.21-3.00) with BMI
35-40 , and 3.23 (2.63-3.95) with BMI ≥ 40. The respective odds ratios for reporting ≥ 14
days of poor physical health during the previous 30 days were 1.04 (0.96-1.14), 1.32
(1.19-1.47), 1.80 (1.52-2.13), and 2.37 (1.90-2.94) and for reporting ≥ 14 of poor mental
health in the previous 30 days 1.02 (0.95-1.11), 1.22 (1.10-1.36), 1.68 (1.42-1.98), and
1.66 (1.32-2.09). Here, too, overweight and obesity affected physical functioning more
strongly than mental functioning (Ford et al. 2001).34
Table 9. Population-based observational studies on weight and HRQL.
Reference Data year Design Country Sex N Age Questionnaire
Lijing et al. 2004 1996 CS USA M&W 7 080 ≥ 65 HSQ-12
Lopez-Garcia et al. 2003 NA CS Spain M&W 3 605 ≥ 60 SF-36
Goins et al. 2003 2000 CS USA M&W 1 542 ≥ 65 Their own
Daviglus et al. 2003 1967-96 L USA M&W 12 409 ≥ 65 HSQ-12
Hassan et al. 2003 2000 CS USA M&W 182 372 ≥ 18 Their own
Heo et al. 2003 1999 CS USA M&W 155 989 ≥ 18 Their own
Yancy et al. 2002 1998 CS USA M 1 168 45-65 SF-36
Damush et al. 2002 1992-6 L USA M&W 7 895 51-61 Their own
Larsson et al. 2002 1997 CS Sweden M&W 5 633 16-64 SF-36
Livingston and Ko 2002 1998 CS USA M&W 32 440 >18 HALex
Burns et al. 2001 1989-95 L Netherlands M&W 4 601 20-59 RAND-36
Ford et al. 2001 1996 CS USA M&W 109 076 ≥ 18 Their own
Trakas et al. 2001 1996 CS Canada M&W 38 151 20-64 HUI3
Okosun et al. 2001 1988-94 CS USA M&W 10 298 17-90 Their own
Doll et al. 2000 1997 CS England M&W 8 889 18-64 SF-36
Brown et al. 2000 1996 CS Australia W 14 779 18-23 SF-36
Fine et al. 1999 1992-96 L USA W 40 098 46-71 SF-36
Manderbacka et al. 1999 1991 CS Sweden M&W 5 306 18-75 Their own
Räikkönen et al. 1999 1983-87 L USA W 120-345 42-50 SF-36
Lean et al. 1999 1995 CS Netherlands M&W 4 040 20-59 SF-36
Lean et al. 1998 1995 CS Netherlands M&W 4 040 20-59 SF-36
Han et al. 1998 1995 CS Netherlands M&W 4 040 20-59 SF-36
Stafford et al. 1998 1985-91 L Great Britain M&W 10 308 35-55 SF-36(physical)
Le Pen et al. 1998 NA CC France M&W 1 000 >18 SF-36
Rumpel et al. 1994 1971-82 L USA W 3 747 25-50 GWB
CC=case-control, CS=cross-sectional, GWB=General Well Being scale, HALex=Health
and Activities Limitation Index, HSQ-12=Health Status Questionnaire, HUI3=Health
Utilities Index-Mark III, L=longitudinal, M=men, NA=not available, RAND-36=RAND-36
Health Survey, SF-36=SF-36 Health Survey, W=women35
Figure 2. Physical functioning (SF-36) in population-based cross-sectional studies.
a) the mean score in physical functioning and b) the odds ratios of poor physical
functioning in different categories of weight. The definition of normal weight,
overweight, obesity, and massive obesity varies slightly between studies.
NA=not available.
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To sum the population-based observational studies it can be concluded, that (1) obese
individuals report deteriorated HRQL, (2) the higher the BMI or waist circumference,
the lower the HRQL, (3) obesity has a greater impact on physical HRQL than on mental
or social HRQL, (4) mental and social HRQL may be affected only among the morbidly
obese and the obese with other chronic conditions, and (5) several factors, such as
sex, age, ethnic group, socio-economic factors, life-style factors, and perceived weight
modify the associations between obesity and HRQL.
2.6.2  Studies among the obese seeking weight loss
Can the results from population based studies be generalised to the obese seeking
weight loss treatment? The SOS–study was the first to report perceived health status
and psychosocial functioning among the obese seeking weight loss treatment. The
SOS QoL includes generic and study-specific HRQL measures that cover health in
general (general health rating index, current health), physical consequences (SIP;
ambulation, home management, work, recreation/pastimes), social and emotional
consequences (SIP; social interaction), mental health (HAD; anxiety and depression,
MACL; pleasantness, activation, calmness, and SE; self-esteem), obesity-specific
problems (TFEQ; restrained eating, disinhibiton, hunger, OP scale; obesity-specific
psychosocial problems, OD scale; intrusion, helplessness). Also included is a global
rating on quality of life.
The cross-sectional data based on the first 1743 patients showed that the severely
obese rated their general health status markedly worse than the population reference
group (Sullivan et al. 1993). Among the severely obese, mental well-being was worse,
and anxiety and depressive symptoms were more common: 20-25% of the severely
obese reported scores exceeding the level of probable severe anxiety and about 10%
the level of severe depression. Women reported worse current health and mental well-
being than men. Also, obese women reported more psychosocial problems due to their
obesity. Obese men reported more dysfunction in social interaction. Somatic morbidity
(joint symptoms, angina pectoris, bed days in hospital) and previous psychiatric
morbidity were strongly associated with current health perception in both sexes. Angina
pectoris and joint symptoms also predicted mental distress and dysfunction in social
life. Other prominent predictors of health and psychosocial functioning were the
number of dieting attempts, physical inactivity during leisure time, and body image.
There are five other surgical studies, that report baseline HRQL data compared with
population reference values; all of these studies used SF-36 as the HRQL measure.
Four of these studies report that the pre-surgery SF-36 scores are markedly lower than
the population reference values in all scales (Choban et al. 1999, Dixon et al. 2001,
Dixon et al. 2002, Dittmar et al. 2003). A study from the Netherlands contradicts these
findings and reports, that there were no significant differences in any of the pre-
operative SF-36 scales compared to the Dutch general population (Hörchner et al.
2001). The pre-operative SF-36 scores were exceptionally high in this study.37
How about the HRQL among the obese seeking non-surgically induced weight loss?
Several studies have examined the HRQL among the obese entering weight loss
treatment with life-style intervention. The SF-36 measured quality of life in 312 patients
seeking outpatient treatment for obesity at a university-based weight management
centre (Fontaine et al. 1996). The authors conclude, that relative to US population
norms, obese persons seeking structured weight loss treatment report substantially
impaired HRQL in all the measured scales and that the impact of obesity varied with
severity of obesity: the morbidly obese reported significantly worse physical, social, and
role functioning, worse general health, and greater bodily pain than did either the mildly
or moderately to severely obese. In analyses adjusted for sociodemographic factors,
BMI, and depression, obese patients reporting pain scored significantly lower in all SF-
36 scales than those not reporting pain (Barofsky et al. 1997). Another study in similar
setting (Fontaine et al. 2000) concluded, that the obese who sought weight loss
treatment were more impaired on the general health, bodily pain, and vitality domains
than those obese who were not currently seeking weight loss treatment.
A Californian study compared the HRQL scores among obese (n=242) and morbidly
obese (n=33) patients in weight loss clinics with the scores among normal weight
individuals recruited from shopping malls (n=67) and gyms (n=75) (Mathias et al.
1997). The obese and morbidly obese reported worse general health, more overweight
distress and depression, and lower self-esteem than the normal weights. An Italian
study among 147 patients of an outpatient obesity clinic showed, that women scored
higher (worse) on the ORWELL97 total score than men (Mannucci et al. 1999). After
adjustment of several confounders, there was no association between the total score
and age or BMI. Patients with a mental disorder scored higher than the others.
A Swedish study described perceived disability among obese female outpatients
(n=57) compared to voluntary normal weight referees (n=22) (Evers Larsson and
Mattsson 2001). Both a pain questionnaire and a disability questionnaire were used to
measure perceived disability, which showed to be much higher among the obese
outpatients. The main problems in physical functioning concerned occupational work in
strenuous positions, strain and pain, sports, walking outdoors or on stairs, and
moderate housework requiring squatting, stooping or lifting. Rising from sofa, pedicure,
and stress incontinence were also causing problems for the obese women. The
perceived disability correlated only fairly to observed functional limitations (rs=0.56,
range 0.14-0.61), underlining the difference between perceived and measured
disability.
In the USA, the IWQOL-Lite measured HRQL in five distinct groups: overweight/obese
community volunteers who were not enrolled in weight loss treatment, clinical trial
participants, outpatient weight-loss programmes/studies participants, participants in
day treatment programmes, and gastric bypass patients (Kolotkin et al. 2002).
Altogether there were 3353 subjects, aged 18 to 90 years, including about 33% men
and 14% African Americans. The authors report that obesity-specific HRQL was more
impaired in the treatment-seeking groups than in the non-treatment seeking groups
across comparable gender and BMI groups. Within the treatment-seeking groups,38
HRQL varied by treatment intensity: the gastric bypass patients had the worst HRQL,
followed by day treatment patients, followed by participants in outpatient weight loss
programmes/studies, followed by participants in clinical trials who had the best HRQL.
Other determinants of HRQL included gender, race, and BMI: the obesity-specific
HRQL was more impaired among those with higher BMI, among Whites, and among
women.
In another study from the USA, the OWLQOL and WRSM measured obesity-specific
HRQL in four distinct populations: validation sample (n=340), clinical trial sample with
an unknown weight loss product (n=1282), and population samples in the USA
(n=1478) and Europe (n=3007). (Patrick et al. 2004). The populations included mainly
White well-educated women with fairly high incomes. The mean OWLQOL scores were
lower (worse) in the clinical trial sample than in the population samples. The scores
decreased with increasing age and with increasing BMI. For the WRSM the mean
scores were higher (i.e. more weight-related symptoms) in the clinical trial sample, with
older age, and with higher BMI. Women had lower scores than men for both
questionnaires. The higher the WRSM score the lower the OWLQOL score.
A Swedish study compared psychosocial functioning measured by the OP scale in four
samples: SOS cross-sectional study (n=6863), SOS-intervention study (n=2128),
XENDOS study (n=3305), and the nonobese in the SOS reference study (n=1017)
(Karlsson et al. 2003). As expected, very low scores on the OP scale were observed in
the normal weight. The scores were moderately higher among the overweight,
especially among women. Markedly higher OP scale scores were observed in the
obese than nonobese subjects indicating more psychosocial problems due to obesity.
Again, obese women scored higher than obese men. About half of the obese women
and one-fourth of the men reported severe to extreme obesity-related psychosocial
problems (OP scale score >60). The obesity-related psychosocial problems were
related to poor mood, and anxiety and depression symptoms.
In conclusion, among the obese persons seeking weight loss, increasing degree of
obesity is associated with broad-range deterioration in HRQL (physical, mental, and
social). Especially manifest are the various obesity-specific problems. Women seem to
be more affected than men. Not only the treatment-seeking status but also the intensity
of treatment influences HRQL responses: the obese seeking surgical treatment report
the worst HRQL. The psychosocial problems among the obese/morbidly obese can be
quite severe, and symptoms of depression and anxiety are common. In this population
it is especially important to measure perceived functionality and well-being, since
perceived and measured disability may correlate only poorly.
2.6.3  Studies among the obese losing weight
If HRQL is especially poor among those seeking treatment, does it improve with weight
loss? The number of published studies examining intentional weight loss and HRQL
has increased during the past few years (table 10) and the interventions have included
diet, exercise, behaviour modification, and pharmacotherapy in varying combinations.39
Two earlier studies among patients with coronary heat disease showed improvements
in HRQL after weight loss with life-style changes. Two cardiac rehabilitation studies
report HRQL data: the first study (Lavie and Milani 1997) included 588 and the other
study (Maines et al. 1997) 591 patients. The patients (not all of them obese)
participated in programme including exercise and education sessions. The obese
patients received dietary advice to lose weight. During the programmes lasting for three
months, the mean weight loss was 1-2% and the patients reported improvements in
many SF-36 domains. However, these studies included normal weight patients and
weight loss was not the primary target of treatment.
Only a few randomised clinical trials have addressed the effects of non-surgically
induced weight loss on HRQL. One early study from Sweden was a 24-month follow-up
assessing mental well-being and functional status among 60 moderately obese (mean
BMI 33 kg/m
2, mean age 43 y) women randomised to a 1 300 kcal lactovegetarian or
non-vegetarian weight loss diet (Karlsson et al. 1994). The Mood Adjective Check List
and Sickness Impact Profile were administered at baseline and at 3, 8, and 24 months.
The final follow-up rate was 75%. There was no difference in weight loss between the
groups (mean weight change in groups not reported). In the analyses the groups were
pooled and the mean weight change was -3.9 kg in the ‘compliers’ and +1.8 kg in the
‘non-compliers’. Mental well-being improved in the short term, but after two years, the
scores deteriorated to lower levels than at baseline. Positive effects on functional
status lasted longer.
Another study randomly assigned 80 women to the group with weight loss intervention
(increased physical activity, low-energy diet, and group support) or to the control group
(Rippe et al. 1998). HRQL was measured by SF-36. This very short (12 weeks) study
without follow-up after the end of intervention showed significantly better weight loss in
the intervention group (-6.07 vs. +1.31 kg) as well as significant improvements in the
scores of physical function (13.5 vs. 1.4), vitality (21.7 vs. 2.9), and mental health (10.4
vs. 2.3) compared to the control group.
An American study examined the effects of a commercial weight loss programme on
weight and HRQL (Lowe et al. 1999). After a newspaper add, >2 700 persons were
invited for an initial evaluation. 1 475 persons attended the evaluation and they were
allocated to treatment arms (Weight Watchers and Self Help) using alternating groups
assignments to consecutive applicants (no true randomisation). After the four-week
follow-up period, the Weight Watchers group lost 1.87 kg and the Self Help group lost
0.77 kg. The Weight Watchers group reported larger increase in vitality score. Other
scales on SF-36 were not included in this study.40
Table 10. The weight loss studies with HRQL measurement.
Reference Design BMI N Treatment arms Follow-up Mean weight
change
Questionnaire
LIFE-STYLE INTERVENTION
Karlsson et al. 1994 RCT 33 60 1)  lactovegetarian hypocaloric
diet
2) regular  hypocaloric  diet
2 y NR SIP, MACL
Rippe et al. 1998 RCT NR 1)  30
2) 14
1) physical  activity
2) control
12 w 1)  -6.1 kg
2) +1.3  kg
SF-36
Lowe et al. 1999 CT NR 985 1)  Weight Watchers
2) Self  Help
4 w 1)  -1,9 kg
2) -0.8  kg
Vitality
Fontaine et al. 1999 BA 31 38 Hypocaloric diet
+ physical activity
+ behaviour modification
13 w -9 kg SF-36
Nieman et al. 2000 RCT NR 1)  22
2) 26
3) 21
4) 22
1) exercise  +  diet
2) diet
3) exercise
4) control
12 w 1)  -8.0 kg
2) -7.8  kg
3) -1.0  kg
4) -0.8  kg
GWB, POMS
Marchesini et al. 2002 CT 1)  37
2) 35
1) 92
2) 76
1) behaviour  modification
2) control
3-5 m 1)  -9.4 kg
2) +0.6  kg
SF-36
Fontaine et al. 2004 BA 31 32 Hypocaloric diet
+ physical activity
+ behaviour modification
1 y -5.3% SF-36
PHARMACOTHE APY
Kolotkin et al. 2001b BA 41 161 Phentermine-fenfluramine 1 y -18% IWQOL-Lite
Samsa et al. 2001 BA 35 1)  631
2) 624
3) 265
Sibutramine/placebo 1) 8-12  w
2) 24-28  w
3) 52  w
NR IWQOL-Lite,
SF-36
Patrick et al. 2004 BA 37 407 Unknown weight
loss product
50-83 w -38.4 kg OWLQOL,
WRSM
NR=not reported, BA=single strand before and after –study, CT=controlled trial,
RCT=randomised clinical trial, GWB=General Well Being, IWQOL-Lite=Impact of Weight
on Quality of Life – Lite, MACL=Mood Adjective Check List, OWLQOL=Obesity and
Weight Loss Quality of Life,  POMS=Profile of Mood States, SF-36=SF-36 Health Survey,
SIP=Sickness Impact Profile, WRSM= Weight-Related Symptom Measure41
The SF-36 measured HRQL in a study, that randomised 38 mildly to moderately obese
patients to either a programme of life-style physical activity or a programme of
traditional aerobic activity (Fontaine et al. 1999). All patients were guided on a low-
energy diet and visited behaviour modification groups. At the end of the 13-week
programme there was no difference in the weight loss result (7.0 kg vs. 8.7 kg in the
life-style and aerobic activity groups, respectively). For the HRQL analyses, the groups
were pooled. Significant improvements were found on physical functioning, physical
role functioning, general health, vitality, and mental health scores. The largest
improvements were on the physical scales. At one year, this same population reported
sustained improvement in general health and vitality, regardless of whether the initial
weight loss was maintained or not (mean weight loss was 5.3% at 1 year) (Fontaine et
al. 2004).
Another RCT allocated 102 women to one of four groups: control, exercise, diet, and
exercise+diet for 12 weeks (Nieman et al. 2000). Exercise training included five 45-
minute walking sessions per week and the diet included 4.2-5.4 MJ per day.
Psychological general well-being and profile of mood states were measured at
baseline, at three weeks, and at the end of study. A total of 91 patients completed the
study. The patients in the diet and exercise+diet groups lost the most weight (7.8 kg
and 8.0 kg, respectively). Psychological general well-being improved significantly only
in the exercise+diet group and most of the improvement occurred during the first three
weeks in the study. The profile of mood states did not show any change in any group.
Cognitive-behavioural therapy was the only intervention in an Italian uncontrolled study
that used the SF-36 to measure HRQL among two groups of obese patients: 92
patients participating in cognitive-behavioural therapy and 76 untreated controls
(Marchesini et al. 2002). In the treatment group, 46 patients had binge eating disorder
at psychometric testing and structured clinical interview. SF-36 was administered at
baseline and at 3-5 months. During the study, the untreated group was weight stable,
but the treatment groups lost 9.4 kg on average. The bingers lost less weight than the
nonbingers (7.7 kg vs. 11.1 kg). However, the HRQL improvement was larger among
bingers than nonbingers, especially in physical role functioning, emotional role
functioning, vitality, mental health, and social functioning. In the treatment group, only
improvement in bodily pain was correlated to weight loss; the authors conclude, that
cognitive-behavioural therapy may have specific effects in obese patients with binge
eating disorder.
Some weight loss pharmacotherapy trials with longer follow-up time have also
included HRQL measurements. IWQOL-Lite measured HRQL among 161 (20 men)
obese patients completing at least one year of outpatient treatment in a weight loss
programme combining phentermine-fenfluramine and dietary counselling (Kolotkin et
al. 2001b). IWQOL-Lite was administered at baseline and at one-year follow-up. At the
end of study, the mean weight loss was 17.6% of baseline weight (16% lost <10% and
as much as 37% lost 20% or more). The study reported that all the five IWQOL-Lite
scales and total score showed significant improvement during the study and these42
improvements were correlated to percentage of weight loss. Clinically meaningful
change in HRQL was defined as a 1.96 SEM reduction in IWQOL-Lite total score: 44%
of those losing <10% and 76% of those losing >20% met this criteria. Physical
functioning and self-esteem were most strongly associated with weight loss.
A pooled analysis of four randomised, double blind, controlled trials of sibutramine (20
mg/daily) vs. placebo examined the association between weight loss and HRQL
measured by SF-36 and IWQOL-Lite (Samsa et al. 2001). The changes in HRQL were
analysed in the short-term (8-12 weeks), medium-term (24-28 weeks), and long-term
(52 weeks) in four categories of weight loss (gain/no change, 0.01-5.00%, 5.01-10.00,
and ≥ 10.01% of weight loss). In the short-term, there was significant relationship with
the weight loss and increases in the scores of general health, change in health since
last year, and the physical summary score of the SF-36 and in health, mobility, and
total scores of the IWQOL-Lite. In the medium-term, weight loss was associated with
increases in general health, physical functioning, physical role functioning, emotional
role functioning, pain, vitality, health-change since last year, and physical summary
scores on SF-36 and in the health, social/interpersonal, mobility, self-esteem, activities
of daily living, and total scores of the IWQOL-Lite. In the long-term, statistically
significant relationships were observed for the physical functioning, physical role
functioning, and vitality score on the SF-36 and for mobility and activities of daily life on
the IWQOL-Lite. Most of the previously mentioned scales showed a dose-response
pattern with larger weight loss associated with greater improvements in HRQL.
In another study the IWQOL-Lite was administered to 122 participants in a weight loss
programme who had initially lost ≥ 5% of their weight and then regained ≥ 5% of their
weight during a mean follow-up 28 months (Engel et al. 2003). The mean age was 46 y
and BMI 41 kg/m
2 at entry. The weight loss programme included treatment with
phentermine-fenfluramine and dietary counselling.  During the follow-up, the mean
weight loss was 19% and the mean weight regain was 10%. Weight loss was linearly
associated with improvement in IWLQOL scores, and weight regain was linearly
associated with deterioration in IWLQOL scores. The patients that reported worst
HRQL at baseline experienced the largest improvement in HRQL with weight loss, but
also the largest deterioration in HRQL during weight regain.
In an American clinical trial (n=407), the OWLQOL and WRSM showed responsiveness
to weight change at 50-83 weeks (Patrick et al. 2004). The mean change in weight was
–38.4 kg. In the categories weight increase, 0-4.9% decrease, 5-9.9% decrease, and
≥ 10% decrease, the mean change in OWLQOL score was 8.87, 10.81, 16.56, and
26.16, respectively. In the categories of weight change, the mean change in WRSM
was 0.12, -1.11, -6.63, and -11.46, respectively. This indicates, that the greater the
weight loss, the larger the improvement in obesity-related feelings and beliefs, and the
larger the decrease in weight-related symptom measures. Of particular interest is the
result that OWLQOL score increased also among those with weight gain. In the
validation study (data not shown here), the WRSM score also showed improvement
with weight gain. Other factors than weight loss, such as taking part in a clinical trial,
must influence the scores.43
The best data to date on weight loss and changes in HRQL comes from surgical
intervention studies collected in table 11, that includes all the prospective studies
published since 1990. Eligible morbidly obese individuals willing to be operated on
have lost weight markedly in long-term follow-up studies with varying surgical
techniques. The largest and methodologically best (with weight stable control group)
study to date is the SOS-study. The two-year follow-up of HRQL has been published
including 487 surgical cases and 487 matched controls (Karlsson et al. 1998). The
mean weight was markedly lower at two years compared to baseline (130.8 kg at
baseline and 100.6 kg in men and 115.1 kg and 88.4 kg in women). The authors report
that poor HRQL was dramatically improved after gastric restriction surgery. Only minor
fluctuations in HRQL scores were observed in the conventionally treated controls.
HRQL scores peaked at 6 or 12 months after intervention with slight to moderate
decrease at the two-year follow-up. The greater the weight reduction, the greater the
HRQL improvement. The two-year results also showed that the greater the weight loss
the greater the improvement in coping, distress, and mood disorders (Rydén et al.
2003). At four years, the mean weight loss was 18.9% after the surgical intervention
while there was some weight gain in the control group (1.1% on average) (Karlsson et
al. 2003). The OP scale scores improved in both surgical and control groups, but the
improvement was markedly higher with large effect sizes of change in the surgical
group. The change in OP scale score was strongly related to the amount of weight
loss. The improvement in obesity-related psychosocial problems was stable over time
in subjects with >15% weight loss. The scores tended to return to baseline levels in
subjects with <5% long-term weight reduction. At four years about 20% of the operated
subjects were classified as non-obese (BMI <30 kg/m
2). OP scale scores in this group
were similar to the scores observed in the non-obese reference group (Karlsson et al.
2003).
Other surgical studies with 6 months to 8 years of follow-up have also reported HRQL
data. Half of these studies have used SF-36 as the HRQL measure, but also other
generic questionnaires (e.g. NHP and SIP) and surgery-specific questionnaires (e.g.
GBQ, GIQLI, and BAROS) have been used. Ten of the studies report HRQL data
before and after gastric banding. Fewer studies report HRQL before and after gastric
bypass or vertical banded gastroplasty. The weight loss after gastric bypass improved
HRQL in all the SF-36 scales, especially physical scales (Choban et al. 1999, Dymek
et al. 2001).
Over 18 months after surgery, the SF-36 scores increased to or over the level
measured in the general population (Choban et al. 1999). Also the areas covered by
the GBQ were improved (Hafner et al. 1991). There are no studies assessing HRQL
with SF-36 after vertical banded gastroplasty. A few studies with 1 to 2 years of follow-
up report sustained improvement in perceived health, physical well-being, physical
performance, mood, and coping/adjustment (Sabbioni et al. 2002) or in the scores of
SIP, MHI, and NHP (Van Gemert et al. 1999, Vallis et al. 2001). One study has
compared gastric bypass, vertical banded gastroplasty, and laparoscopic gastric
banding (Hell et al. 2000). The BAROS was the only measure of HRQL in this study.44
Table 11. The prospective HRQL studies with weight loss surgery
(published since 1990).
Reference Design BMI N Intervention Follow-up Mean weight
change
Questionnaire
Malone and
Alger-Mayer 2004
BA 48 109 Gastric bypass 1 y -26-69% EWL SF-36
Dymek et al. 2001 BA 57 32 Gastric bypass 6 m -49% EWL SF-36
Choban et al. 1999 BA 51 107 Gastric bypass >1.5 y -36 kg SF-36
Hafner et al. 1991 BA NR 118 Gastric bypass 1 y -35 kg GBQ
Sabbioni et al. 2002 BA 46 82 Vertical banded gastroplasty 2 y -14 kg/m
2 Their own
Lee et al. 2002 BA 43 223 Vertical banded gastroplasty
(laparoscopic)
2 y -12 kg/m
2 GIQLI
Vallis et al. 2001 BA 48 89 Vertical banded gastroplasty 1 y -15 kg/m
2 OAS, MHI, SIP
Van Gemert et al. 1999 BA 47 21 Vertical banded gastroplasty 2 y -48 kg NHP I, NHP II,
VAS
Zinzindohoue et al. 2003 BA 44 185 Gastric banding (laparoscopic) 2 y -52% EWL BAROS
Weiner et al. 2003 BA 47 100 Gastric banding (laparoscopic) 8 y -59% EWL SF-36, BAROS
Dittmar et al. 2003 BA 48 26 Gastric banding (laparoscopic) 17 m -21 kg SF-36
Dixon and O’Brien 2002 BA 48 50 Gastric banding (laparoscopic) 1 y -38% SF-36
Hörchner et al. 2001 BA 41 42 Gastric banding (open surgery) 2 y -9 kg/m
2 SF-36
Freys et al. 2001 BA 48 73 Gastric banding (laparoscopic) 2 y -47% EWL GIQLI
Dixon et al. 2001 BA 45 69 Gastric banding (laparoscopic) 4 y -51% EWL SF-3645
Weiner et al. 1999 BA 48 287 Gastric banding (laparoscopic) >1.5 y -47 kg Their own
Hörchner and
Tuinebreijer 1999
BA 40 42 Gastric banding 1 y -23 kg SF-36
Larsen et al. 1990 BA 42 30 Gastric banding 3 y -32 kg Battery
Karlsson et al. 2003 CT 1)  41-43
2) 39-40
1) 286
2) 269
1) bariatric  surgery
2) control
4 y -18.9%
+1.1%
OP scale
Hell et al. 2000 CT 1)  30
2) 30
3) 30
1) 47
2) 47
3) 45
1) gastric  bypass
2) vertical  banded  gastroplasty
3)  gastric banding (laparoscopic)
1) 40  m
2) 20  m
3) 60  m
NR BAROS
Karlsson et al. 1998 CT 1)  41-42
2) 39-41
1) 487
2) 487
1) bariatric  surgery
2) control
2 y 1)  -27-30 kg
2) -0.7  kg
SOS QoL
NR=not reported, BA=single strand before and after study, BAROS=Bariatric
Analysis and Reporting Outcome System, CT=controlled trial, % EWL=relative
loss of excess weight, GBQ=gastric bypass questionnaire,
GIQLI=Gastrointestinal Quality of Life Index, MHI=Mental Health Inventory,
NHP=Nottingham Health Profile, OAS=Obesity Adjustment Survey, OP
scale=Obesity-related problems scale, QLS=Quality of Life Scale, SF-36=SF-36
Health Survey, SIP=Sickness Impact Profile, SOS QoL=Swedish Obese Subjects
Quality of Life Survey, VAS=visual analog scale46
Over 3 to 8 years of follow-up, a significant improvement in BAROS scores was evident
in all the groups, but the results favoured gastric bypass over the purely restrictive
procedures.
In conclusion, based upon the intervention studies, weight loss seems to improve
HRQL and this improvement is dependent on the amount of weight loss: the larger the
weight loss, the larger the improvement. Mental and social domains seem to improve in
the short term, whereas physical functioning, mobility, and vitality seem to improve in
the longer term. Weight regain has been associated with both deterioration and
improvement in obesity-specific HRQL measures. Weight loss surgery produces
marked and sustained weight loss and HRQL improvements.47
3  AIMS OF THE PRESENT STUDY
The aim of this thesis was to examine the associations between obesity, intentional
weight loss, weight loss maintenance and HRQL (generic and obesity-specific) in
clinical studies.
The main questions were:
Study  I  and  III Does weight loss with VLED and behaviour modification improve
HRQL in obese patients?
Do these responses differ during active weight loss and weight loss
maintenance?
Study II Does weight loss with VLED and behaviour modification increase
testosterone level and improve sexual functions in obese men?
Do these responses differ during active weight loss and weight loss
maintenance?
Study  IV Does weight loss with sibutramine produce HRQL benefits over
placebo in obese patients with type 2 diabetes?
Study V Does weight loss with gastric bypass or vertical banded gastroplasty
improve HRQL in obese patients?
The aim was also to describe:
•   HRQL in obese patients before treatment
•   The associations between changes in weight and questionnaire scores
•   The effects sizes of HRQL changes
•   HRQL changes in categories of weight loss
•   The role of HRQL in predicting success of weight loss maintenance48
4 PATIENTS  AND  METHODS
4.1  Study design and patient selection
This thesis collects data and results from five clinical weight loss studies. Studies I, II,
and IV are randomised clinical trials, studies II and V are single strand follow-up
studies. Figure 3 presents the designs of these studies.
4.1.1  Studies I and II: a randomised clinical trial
Studies I and II are based on the same clinical population. The study took place in the
Helsinki University Central Hospital, Peijas Hospital in Finland. This was a randomised
clinical trial involving obese (BMI ≥ 35 kg/m
2, age 18-60 years) men recruited by a
newspaper add. In a phone-interview the men were excluded if they had type 1
diabetes mellitus, over five years since the diagnosis of type 2 diabetes mellitus,
excessive intake of alcohol or other substances, or any contraindication to VLED. This
was a study that also examined sex-steroids and sexual functions, therefore we
excluded single men and men with primary testicular failure or prostate cancer. After
the phone-interview the eligible patients underwent a medical examination in order to
check the inclusion and exclusion criteria and to evaluate suitability for treatment with
VLED and behaviour modification. The screening took place in the year 1999 and the
study in the year 2000.
We screened a total of 72 men and excluded 34. The accepted study patients were
randomised: 19 into the treatment and 19 into the control group. Age and BMI stratified
randomisation, which was carried out in blocks of four using a computer-generated
table of random numbers. The treatment group took part in a weight loss programme
comprising 10 weeks on VLED and 4 months of weekly behaviour modification visits in
groups. The treatment group was followed without any structured weight loss
maintenance programme for 4 months after treatment (amounting to 5.5 months after
the VLED period). The control group was advised to maintain their current life-style
without any attempts to lose weight until the end of study. The men in control group
visited the obesity unit at the data collection points, but did no receive any intervention.
Weight was measured and HRQL questionnaires were administered at baseline, at the
end of VLED period, at the end of group visits, and at the end of study. The control
group started the weight loss programme after the study was finished.
4.1.2  Study III: a single strand follow-up study
Study III was conducted in the Helsinki University Central Hospital, Peijas and Meilahti
Hospitals in Finland. This was a single strand follow-up study among the patients of
two obesity units. Local general/occupational practitioners and hospital specialists
referred obese (BMI ≥ 35 kg/m
2, age 18-60 years) men and women, whose previous
weight loss attempts had failed, who had obesity-related comorbidity requiring weight
loss, and who were motivated to participate in a structured weight loss programme.49
Figure 3. The study designs.
Study I and II Study III
Study IV Study IV
VLED=very-low-energy diet
w=week
m=month
Screened (n=72)
Randomised
(n=38)
Treatment
group (n=19)
Control
group (n=19)
End of VLED
(n=18) 10 w (n=17)
End of group
(n=17) 4 m (n=17)
(n=17)
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follow-up
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2-year follow-up
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Patients were excluded from the study if they had obesity due to a secondary aetiology,
had  a significant  psychiatric disorder, had a  severe eating  disorder, were  eligible  for
bariatric surgery, or preferred individual weight loss therapy. In order to assure
motivation, all eligible patients were asked to consider taking part in our program for a
few weeks before making their final decision to sign in. The screening was carried out
in 1998-1999.
The treatment was identical to the weight loss programme in study I. The only
difference is that the follow-up time was extended to two years after treatment. The
treatment programmes were carried out in the years 1999-2000. The obesity unit
provided no structured weight loss maintenance programme, but the patients were free
to contact their own general/occupational practitioner after the programme. Weight was
measured and HRQL questionnaires were administered at baseline, at the end of
group visits, and at 1- and 2-year follow-up visits. The final follow-up visit of the last
treatment group was in 2002.
4.1.3  Study IV: a double-blind, randomised clinical trial
Study IV started in 1996 and took place at several primary health care centres in
Finland. Obese (BMI ≥ 28 kg/m
2, age 25-70 years) men and women with type 2
diabetes treated with diet only were screened for a double-blind, randomised clinical
trial on the effects of sibutramine on weight and glycaemic control. They were eligible
for the study if treated by diet alone, had a relatively stable weight (<5 kg weight
change in previous 3 months), and had no nephropathy, proliferative retinopathy,
exudative maculopathy, or insulin deficiency (ketonuria or fasting C-peptide <0.3
mmol/l). Patients with significant illnesses such as uncontrolled hypertension,
uncompensated heart failure, symptomatic coronary disease, and renal or hepatic
failure and medications that could affect body weight were excluded. Women of
childbearing potential not taking adequate contraception were also excluded.
Eligible patients entered a 2-week run-in –period with a hypocaloric (700-kcal daily
deficit) diet before randomisation. The patients were randomly assigned to either
sibutramine (15 mg daily) or placebo group. After randomisation, the patients visited
the obesity clinic monthly: each visit included the measurement of weight and
enforcement of dietary advice. Blood samples for HbA1c and fasting glucose were
drawn and questionnaires were administered at randomisation and every 3 months
during the 12-month follow-up.
4.1.4  Study V: a single strand follow-up study
Study V was realised in the Lund University Hospital in Sweden. Consecutive patients
scheduled for a primary procedure at the obesity unit were offered participation in the
study. Indication for surgery was obesity with a BMI >35 kg/m
2 and at least three
professionally led attempts of failed conservative treatment. The patients were
operated on in the years 2000-2001. The operative method was chosen according to
departmental policy; there was no randomisation between methods. The choice of
operative method was that diabetes and/or a BMI >45 kg/m
2 indicated GBP; all other51
patients had VBG. Weight was measured and the HRQL questionnaires were
administered at baseline, and at 6- and 12-month follow-up visits.
4.2  Weight loss methods
In studies I, II and III the patients lost weight with very-low-energy diet (Nutrifast ,
Leiras, Helsinki, Finland), which was the patients’ only diet for 10 weeks. They also
took part in behaviour modification, which was carried out at weekly group visits at the
obesity unit. The VLED provided 52 g of protein, 64 g of carbohydrates, 8 g of fat,
vitamins, trace elements, and minerals daily with an energy intake of 2200 kJ/day. A
small amount of low energy vegetables was allowed. A normal diet was gradually
introduced after the VLED period. The behaviour modification programme was based
on the LEARN Programme for Weight Control (Brownell 1989). The core elements of
behaviour modification were goal setting, nutrition (decrease in fat intake and increase
in complex carbohydrates and fibre intake), exercise (mainly life-style exercise), self-
monitoring, stimulus control, problem solving, cognitive restructuring, and relapse
prevention.
In study IV the patients visited the study centre every month. They received behaviour
modification and dietary advice aiming at a hypocaloric (700 kcal daily deficit) diet. The
study groups received either sibutramine 15 mg once daily or placebo once daily.
In Study V all operations were open and performed by the same surgeon. The gastric
bypass technique results in a gastric pouch emptying to a jejunal loop through an outlet
with an area of roughly 200 mm
2. VBG was performed with an isolated gastric pouch
with a volume of 12-16 ml. A Goretex band was used, 6 mm wide and with a measured
circumference of 50 mm (+ overlap). This procedure gives a pouch that empties into
the main stomach through a reinforced outlet with an area of approximately 95 mm
2.
No patient had a gastrostomy catheter. All patients were allowed liquids from the first
postoperative day. There were no perioperative complications and all patients left
hospital on the third or fourth postoperative day.
4.3 Assessments
The mean outcome measures in all studies were weight and questionnaires measuring
health-related quality of life. In some studies blood samples and data on blood
pressure and pulse were collected. Table 12 gives the outcome measures and their
collection time.
4.3.1  Weight and BMI
Weight was measured in all studies using a calibrated scale with the patient wearing
light indoor clothing and no shoes. BMI was calculated by dividing the weight (in
kilograms) by the height squared (in metres).52
Table 12. The study assessments.
Baseline 3 to 4
months
1
6
months
8-9
months
12
months
16
months
28
months
Weight ALL I, II, III, IV IV, V I, II, IV IV, V III III
Laboratory II, III, IV II, III, IV II IV III III
BP, pulse IV IV
OP scale I, III I, III I III III
RAND-36 I, III, IV I, III, IV IV I, II, IV IV III III
SF-36 V V V
IIEF&SAS II II II
1 at the end of group visits in studies I, II, and III
BP=blood pressure, IIEF=International Index of Erectile Function, OP-scale=Obesity-
related problems, RAND-36=RAND-36 Health Survey, SAS=Sexual Activity Scale, SF-
36=SF-36 Health Survey
4.3.2  The Obesity-related problems scale
Obesity-related HRQL was measured with the Obesity-related problems scale (OP
scale) in studies II and III. This 8-item questionnaire is part of the battery (SOS QoL)
that was developed for the Swedish Obese Subjects study at the Health Care
Research Unit, Sahlgrenska University Hospital, Gothenburg, Sweden. The OP scale is
a self-assessment instrument that measures the impact of obesity on psychosocial
functioning.
The questionnaire asks how bothered the subject is by his/her obesity as regards:
1.  private gatherings at home
2.  private gatherings at a friend’s or relative’s home
3.  going to restaurants
4.  participation in community activities (courses, etc.)
5.  holidays away from home
6.  trying on and buying clothes
7.  bathing in public places
8.  in intimate relations with a partner
Each item has a 4-point scale ranging from definitely bothered to definitely not
bothered. The OP scale has a score range from 0 (no impairment) to 100 (maximal
impairment).
The psychometric properties of the OP scale have been tested in four Swedish
samples: 6863 subjects in the SOS cross-sectional study; 2128 in the SOS intervention
study; 1017 nonobese subjects in the SOS reference study; and 3305 obese subjects
in the XENDOS study (Karlsson et al. 2003). It was also tested in subgroups by sex,
age, and BMI. Scaling assumptions were consistently satisfied (strong construct
validity). In exploratory factor analysis the OP factor was reproduced across samples
and subgroups (strong homogeneity). Multipartite/multi-item analysis demonstrated,
that all items contributed to the total scale score (solid item-convergent validity). The
OP scale was tested in relation to other HRQL scales in the SOS QoL. Scale-to-scale53
correlations were low to moderate (solid item-discriminate validity). All this suggests
that the OP scale provides sound and unique information on HRQL of obese subjects.
An OP scale score <40 indicates mild impairment of psychosocial functioning and
mental well-being, an OP scale score 40 to 59 indicated moderate impairment in
psychosocial functioning and increased risk for affective disorders, and a score ≥ 60
indicates severe to extreme impairment in psychosocial functioning and extremely high
risk for mood disorders. The minimal clinically important difference is suggested to be
about 4 points (Karlsson et al. 2003).
The OP scale was adapted to Finnish using the procedures of forward and backward
translation and pilot testing on obese individuals who also participated in a debriefing
interview. The evaluation was done in collaboration with the developers of the original
Swedish questionnaire. Three native Finnish speakers involved in obesity research did
the forward translations. In the question 7, sauna was added because of its profound
importance in the Finnish culture. A native bilingual (Finnish and Swedish) nurse, who
has also specialised in behaviour modification, back translated the provisional forward
translation. There was good agreement between the back translation and the original.
The provisional forward translation was considered semi-final and pilot-tested in 18
Finnish obese patients entering treatment in an obesity clinic in Helsinki, Finland. The
patients readily accepted the questionnaire. In the structured interviews, there were 2
comments on the semi-final version. One patient noted, that the response category ”ei
juurikaan” was not good Finnish. It was changed to ”vain vähän” in the final version.
Another patient noted on question 1, that she has two separate ”families”, one with her
sisters and another with her boyfriend. Obesity bothers her differently in these two
families. The question was not changed in the final version.
4.3.3  The SF-36/RAND-36 Health Survey
The Medical Outcomes Study (MOS) was an American project aimed at developing
outcome measures for health care. In the late 1980’s the SF-20 was developed as a
compromise between previously used lengthy questionnaires and global questions.
Later the goal was to further enhance content validity of the previous health surveys
and to construct scales that were likely to more precisely detect medically and socially
relevant differences in health status and changes in health over time. The SF-20
evolved into the SF-36. The 8 concepts in the SF-36 were selected out of around 40 to
cover the most generic, universally applicable domains of functioning and well-being
within the conceptual framework of physical and mental health (Ware and Sherbourne
1992). The SF-36 was translated and adapted into Swedish (Sullivan et al. 1995) using
methods later adopted by The International Quality of Life Assessment (IQOLA)
Project, which translated and adapted the SF-36 in numerous languages and cultures
(Bullinger et al 1998, Ware and Gandek 1998).
During the IQOLA project the copyright was settled in court. Nowadays these 36 items
are distributed by RAND as the RAND 36-Item Health Survey 1.0 (Hays et al. 1993), by
the Psychological Corporation as the RAND-36 Health Status Inventory (Hays et al.54
1998), by the Medical Outcomes Trust and the QualityMetric Inc. as the SF-36 Health
Survey (Ware et al. 1993, www.sf-36.org). The versions are virtually identical, but
contain minor modifications and differences in scoring. Different distributors also score
the physical and mental health summary scores differently.
The generic HRQL measure RAND-36 was used in studies I, III, and IV. The SF-36
was used in study V. These instruments contain exactly the same questions, but the
scoring of general health and bodily pain differs slightly. The questionnaire measures
eight different domains, four in the area of physical health (physical functioning,
physical role functioning, bodily pain, general health) and four in the area of mental
health (mental health, emotional role functioning, vitality, social functioning). The item
content is presented in table 13. All scale scores range from 0 to 100, with 100
representing optimal functioning/well-being. The minimal clinically important difference
is cautiously suggested to be 3-5 points (Samsa et al. 1999, Hays and Morales 2001).
Table 13. The content of items in RAND-36/SF-36 –questionnaire
1
Scale Summary of content Items
Physical
functioning
Extent to which health limits physical activities, such as self-
care, walking, climbing stairs, bending, lifting, and moderate
and vigorous exercises
10
Physical role
functioning
Extent to which physical health interferes with work or other
daily activities, including accomplishing less than wanted,
limitations in the types of activities, or difficulty in performing
activities
4
Bodily pain Intensity of pain and the effect of pain on normal work, both
inside and outside home
2
General health Personal evaluation of health, including current health,
health outlook, and resistance to illness
5
Mental health General mental health, including depression, anxiety,
behavioural-emotional control, general positive affect
5
Emotional role
functioning
Extent to which emotional problems interfere with work or
other daily activities, including decreased time spent on
activities, accomplishing less, and not working as carefully as
usual
3
Vitality Feeling energetic and full of life versus feeling tired and worn
out
4
Social
functioning
Extent to which physical health or emotional problems
interfere with normal social activities
2
Health-change
since last year
Personal evaluation of health-change during the past year –
much worse to much better
1
1 The ordering of mental health concepts differs in SF-36.55
These questionnaires have been translated and adapted to several languages,
including Finnish (Aalto et al. 1999) and Swedish (Sullivan et al. 1994). In Finland two
independent research groups translated this questionnaire (RAND-36 in Aalto et al.
1995 and SF-36 in Hagman 1996). The work was based on the same English
questions, but the translations vary slightly (Aalto et al. 1997). The two translations
have never been tested simultaneously and the population reference values of one
translation are not valid for the other translation.
The scaling properties and construct validity of the Finnish RAND-36 were tested
among randomly selected Finns (3000 aged 18-79 and 400 aged 65-79 years). The
data completeness, the convergent-discriminant validity of items and internal
consistencies as well as ceiling and floor effects in the subscales were comparable with
the results obtained for RAND-36 in international studies. In the factor analysis, the
subscales appeared to reflect two constructions: physical and mental health. In the
Finnish study, the general health scale correlated more strongly to the physical health
construct, and the vitality scale correlated more strongly to the mental health construct,
than was expected on the basis of the international studies. Strong and consistent
associations with different morbidity indicators (chronic illnesses, visits to doctor,
psychosomatic stress symptoms further supported the construct validity).
The Finnish RAND-36 has not been tested with respect to BMI in the general
population. However, the Swedish SF-36 was administered to 5633 men and women
aged 16 to 64 years born in Sweden (Larsson et al. 2002). The SF-36 scores were
compared between subjects with normal weights, overweight, and obesity. In the age
group 16 to 34 years, overweight was associated with impaired physical functioning
and general health among men and women. Obesity was associated with impairments
in all the scales (except for mental health and emotional role functioning) among men,
but among women only physical functioning, bodily pain, and general health were
impaired. In the age group 35 to 64 years, overweight was associated with lower
scores on all the physical scales and emotional role functioning among men, and on all
the physical scales and vitality among women. Obesity was associated with
impairments in physical functioning, and general health among men, but in all the
scales among women. Severe obesity (BMI ≥ 40 kg/m
2, n=30) was associated with
significantly worse SF-36 scores than overweight. The SF-36 managed to discriminate
between people in different categories of overweight and obesity.
4.3.4  The International Index of Erectile Function and the Sexual Activity
Scale
The International Index of Erectile Function (IIEF) is a 15-item questionnaire
addressing five domains of male sexual functions: erectile function (6 items, 5- to 6-
point scales, score 1 to 30), orgasmic function (2 items, 6-point scales, score 0 to 10),
sexual desire (2 items, 5-point scales, score 2 to 10), intercourse satisfaction (3 items,
6-point scales, score 0 to 15), and overall satisfaction (2 items, 5-point scales, score 2
to 10) (Rosen et al. 1997). The higher the score the less impairment in respective
sexual function. The instrument was developed in the United Kingdom and the MAPI56
Research Institute, Lyon, France, has translated it to 10 languages (including Finnish).
The questionnaire has been tested for psychometric properties in a clinical trial sample
of erectile dysfunction patients, a comparison sample of functional, age-matched
volunteers, and a validation sample of both patients with erectile dysfunction and
normal volunteers. The questionnaire showed good reliability, construct validity, and
responsiveness to treatment.
The Sexual Activity Scale (SAS) comprises three items: sexual activity, sexual
enjoyment from sex acts, and satisfaction with the sexual relationship (Kreuter et al.
1996). Only one question was used in study II: "How often do you and your partner
engage in sexual activity, with or without intercourse?". It has a scale range from 1 to 8
corresponding "never" to "every other day". The minimal clinically important difference
for IIEF and SAS are unknown.
4.3.5 Biochemical  analyses
Studies I and V did not include biochemical data. In studies III and IV, blood samples
for HbA1c and glucose were drawn after an overnight fast (>8 h). In study III the
samples were analysed at Peijas and Meilahti Hospitals, and in study IV at a central
laboratory.
In study II, the blood samples were drawn from a forearm vein after a 10-hour fast
between 7 am and 9 am. Whole blood was processed and the serum samples were
stored at -20° C until analyses were performed at an accredited testing laboratory. We
calculated serum free testosterone (pmol/l) = serum testosterone (nmol/l) x 10 x [2.28 -
1.38 x log (SHBG (nmol/l) x 0.1)]. Testosterone was quantified with a direct coated tube
radioimmunoassay (Spectria®, Orion Diagnostica, Espoo, Finland) and estradiol with a
radioimmunoassay (Clinical Assays(tm), DiaSorin, Saluggia, Italy) after an in-house
diethylether extraction. Estrone was quantified with extraction with diethylether &
radioimmunoassay (PerkinElmer lifesciences®, Waalac, Finland). SHBG, LH, FSH and
prolactin were quantified with time-resolved immunofluorometric assays on an
automatic immunoanalyser (AutoDELFIA®, Wallac, Finland). Insulin and leptin were
quantified with radioimmunoassay (Phadeseph®, Pharmacia, Uppsala, Sweden and
Linco Research, St. Charles, Missouri, respectively). The assay protocols followed
those outlined by the manufacturers except for the additional extraction for the estradiol
assay. The detection limit, intra-assay and interassay variations were 18 pmol/L, <5%
and <10% respectively for estradiol; 55 nmol/L, 8.9%, 14% for estrone; 100 pmol/l,
<8%, <7% for testosterone; 0.5 nmol/L, <5%, <3% for SHBG; 0.05 IU/L, <4%, <6% for
FSH; 0.05 IU/L, <5%, <5% for LH; 2mU/L, <3%, <4% for prolactin; 2.5 mU/L, <9%,
<10% for insulin and 0.5 mg/L, <8%, <8% for leptin.
4.4 Statistics
All analyses were done using SPSS 10.0 for Windows. The baseline characteristics
and HRQL scores were compared between subgroups using independent-samples t57
test or one-way ANOVA for continuous variables and chi-square test for categorical
variables.
The longitudinal data was analysed using the general linear modelling, repeated
measure procedure with one factor for comparisons between subjects (treatment or
control group) and one factor for comparisons within subjects (each follow-up
measurement compared to baseline) in studies I, II and IV. Study III and V did not
include a control group, therefore the general linear modelling, repeated measure
procedure was used with a factor for comparisons within subjects (each follow-up
measurement was compared to baseline). Since study V was not a randomised
controlled trial and the selection criteria differed between groups, no analyses for
between groups differences in weight or HRQL change were performed.
In study IV, the changes from baseline to endpoint in the following variables were
evaluated by analysis of covariance with factors for treatment group and centre with
baseline as a covariant: body weight, HbA1c, and vital signs
The association between changes in weight and HRQL scores was analysed using
Pearson's bivariate correlation with a two-tailed test of significance. Independent-
samples t test or one-way ANOVA examined the differences in changes in HRQL
scores between subgroups.
In study IV stepwise backward multiple regression examined the models with predictive
value of baseline HRQL and early changes in HRQL with weight loss (first 3 months)
on weight loss at 12 months. The sum of four dichotomised HRQL variables
determined the clustering of the selected variables. One-way ANOVA examined the
weight loss differences between these clusters.
The p-value <0.05 was considered statistically significant for all analyses, though near
significant p-values are also presented when applicable. The effect size was calculated
for each questionnaire scale [ (mean12 months – meanbaseline)/sdbaseline] . The generally
accepted cut-offs are 0.20 for small effect size, 0.50 for moderate effect size, and 0.80
for large effect size (Cohen 1978).
4.5 Study  ethics
In studies I and II the Peijas Hospital Ethical Committee approved the study protocol. In
study III the Helsinki University Central Hospital and Peijas Hospital Ethical
Committees approved the study protocol. In study IV the ethics committees of all
centres approved the study. In study V the Lund University ethics committee approved
this study as part of the LOST protocol. All subjects received written and oral
information before signing the consent form. We treated all study subjects according to
The Helsinki Declaration (World Medical Association 2000).58
5 RESULTS
5.1  Baseline characteristics and weight loss
Due to the differences in recruitment methods and inclusion/exclusion criteria, the
study populations varied with respect to sample size, sex distribution, and BMI. The
surgical study V had the youngest and heaviest patients. The sibutramine study IV
included patients with the highest mean age and lowest mean BMI. The proportion of
men ranged from 20% (study V) to 100% (study I and II). The pooled analysis of all the
included studies showed, that at baseline the total number of patients was 474, the
mean age was 48.4 years, the mean BMI was 38.7 kg/m
2,
 and 41% of them were male.
The baseline characteristics of patients in studies I-IV are summarised in table 14.
Table 15 presents the mean weight loss and figure 4 the mean BMI at baseline and
during follow-up in studies I-V.
Studies I and II: Randomisation resulted in 19 men in the treatment group and 19 men
in the control group. The groups were similar with respect to BMI and age. One and
three men had diabetes in the treatment and control groups, respectively. The dropout
rates during the study were 16% (n=3) and 11% (n=2) in the treatment and control
groups, respectively. The men in the treatment group lost weight rapidly with VLED as
the only diet for 10 weeks, by the end of the group visits the mean(sd) weight loss was
17.0(7.4)%. During the subsequent 4-month follow-up, there was some weight regain.
The control group remained weight stable throughout the study.
Study III: Among the 126 patients entering treatment, the mean BMI did not differ
between sexes, but the mean waist circumference was significantly larger in men. The
prevalence of type 2 diabetes was 20% among women and 37% among men.
Dyslipidaemia, hypertension, and obstructive sleep apnoea were also more prevalent
among men. Degenerative joint diseases were more common among women. The
drop-out rate during treatment was 21%, the subsequent dropout rate was 14% by 1-
year and 33% by 2-year follow-up (53% of those entering treatment completed the
study). By the end of group visits, the mean(sd) weight loss was 12.5(5.6)%. During the
subsequent 2-year follow-up, the mean(sd) regain of lost weight was 65.8(138.4)%.
Study IV: Among this population of obese patients with type 2 diabetes, there were
three and one early withdrawals in the sibutramine and placebo groups, respectively.
Among the remaining population (intention to treat –population, n=232), a total of 102
patients on sibutramine (92%) and 108 patients on placebo (89%) completed the study.
There was no significant change in the glycaemic control in either study group during
the trial. The mean change in systolic blood pressure was 4.1 mmHg in the sibutramine
group and 3.6 mmHg in the placebo group (p=0.81).  The mean change in diastolic
blood pressure was 1.7 mmHg and –0.2 mmHg in the sibutramine and placebo groups,
respectively (p=0.06). The mean increase in pulse rate in the sibutramine group was
5.5 beats per minute compared to 1.3 beats per minute in the placebo group (p<0.001).59
Figure 4. Mean BMI at baseline and during follow-up in studies I-V.
VLED+BM=very-low-energy diet and behaviour modification, GBP=gastric bypass,
VBG=vertical banded gastroplasty
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Table 14. The patient characteristics at baseline in studies I-IV.
Study I and II Study III Study IV I, II, and IV
pooled
1
Healthy
Finns
2
N 38 126 236 401 897
Males (%) 100 34 41 46 -
Age, years 46.6(9.8) 48.2(11.1) 52.5(8.7) 50.6(9.9) -
Weight, kg 125.3(12.6) 123.3(27.3) 98.4(16.7) 125.3(12.6) -
BMI, kg/m
2 39.3(3.4) 42.8(6.2) 35.3(5.1) 37.8(6.2) -
RAND-36
Physical functioning 73.7(20.0) 57.1(24.1) 79.7(16.6) 72.3(21.9) 91.7
Physical role functioning 66.9(39.6) 59.3(41.2) 79.5(30.1) 72.2(35.9) 87.3
Bodily pain 73.6(23.4) 62.2(28.8) 78.1(24.3) 72.9(26.6) 85.8
General health 59.6(20.7) 49.4(20.1) 64.5(19.1) 59.6(20.6) 72.9
Mental health 73.3(22.7) 69.7(20.3) 81.7(15.4) 77.3(18.6) 82.3
Emotional role functioning 73.9(35.3) 67.8(39.4) 82.9(29.7) 77.6(34.0) 70.3
Vitality 60.7(24.7) 53.6(25.1) 72.6(18.0) 65.7(22.7) 77.9
Social functioning 81.8(23.1) 76.1(25.4) 89.5(16.4) 84.7(21.0) 87.9
OP scale 55.2(22.9) 61.9(24.6) - 60.1(24.3)
3
Values are mean(sd) unless stated otherwise.
1 pooled data from studies I, II, and IV
2 in Aalto A-M et al. 1999
3 n=16461
The weight loss at 12 months was significantly greater in the sibutramine group (7.3%)
than in the placebo group (2.4%).
Study V: A total of 74 patients were operated on. Gastric bypass was the operation for
48 and vertical banded gastroplasty for 26 patients. The GBP group was significantly
heavier at baseline: mean(sd) BMI was 46.4(8.4) kg/m
2 and 38.4(2.3) kg/m
2 in the GBP
and VBG groups, respectively. There were 14 men (29%) in the GBP group and only 1
man in the VBG group. The number of patients followed up to one year were 36 (75%)
for GBP and 22 (85%) for VBG. At 12 months, the mean(sd) weight loss was
34.0(10.2)% and 26.1(5.9)% for GBP and VBG, respectively. At the 12-month follow-
up, the mean(sd) BMI was 30.1(4.3) and 28.9(1.7), respectively.
Table 15. The mean(sd) weight change (% of baseline weight) during follow-up.
3-4 months
1 6
months
8
months
12
months
16
months
28
months
Study I and II
(treatment)
2
-17.0(7.4) -13.9(7.8)***
Study I and II
(control)
2
-1.1(3.0) +0.1(3.8)
Study III
3 -12.5(5.6) -6.0(7.1) -2.6(7.5)**
Study IV
2
(sibutramine)
-5.0(2.9) -7.3(5.3)***
Study IV
2
(placebo)
-1.7(2.6) -2.4(4.8)
Study V
3
(GBP)
-26.7(6.6) -34.0(10.2)***
Study V
3
(VBG)
-23.3(4.8) -26.1(5.9)***
1 at the end of group visits in studies I, II, and III.
2 intention to treat –population
3 completers population
GBP=gastric bypass, VBG=vertical banded gastroplasty
***=p<0.001, **=p<0.01, the p-values are for weight loss result at the end of study
relative to baseline in studies III and V, and to control group in study I and II, and to
placebo in study IV.
5.2  HRQL in obese patients entering weight loss treatment
Table 14 summarises the baseline HRQL scores in the study populations I, III, and IV.
It also gives the average scores of RAND-36 among healthy Finns (Aalto A-M et al.
1999). Study V was excluded from the pooling, because SF-36 instead of RAND-36
measured HRQL in study V and the scores may not be entirely comparable due to
differences in algorithms, translation and population reference values. High score on
RAND-36 and low score on OP scale indicates good HRQL. The lowest baseline
scores on RAND-36 were seen in the study III. The population in study I had somewhat
better scores in every RAND-36 scale. The best scores in all the scales were among
the patients in study IV: compared to healthy Finns, the physical scale scores were62
worse, but the mental health scales were comparable to healthy Finns. The mean
score on emotional role functioning was even better than in the general population.
When the study populations were pooled, increasing degree of age was associated
with increasing scores on mental health and vitality (figure 5). Men scored ≥ 5 points
higher on physical functioning and vitality. Increasing degree of BMI was associated
with decreasing scores on physical functioning, bodily pain, general health, mental
health, and vitality. The mean(sd) OP scale score was 60.1(24.3) in the pooled
population (n=164). Increasing degree of age and BMI were associated with higher
score indicating more obesity-related psychosocial problems (figure 6). Women scored
higher than men on the OP scale.
5.3  HRQL changes with VLED and behaviour modification
In Study I, the RAND-36 scores did not change much in the control group during the 8-
month study. For an unknown reason, the physical role functioning score showed an
increase. In the treatment group, both the physical and mental scales on RAND-36
increased and the OP scale score decreased during the VLED period, but especially
the mental scale scores started to turn back towards baseline level during the weight
loss maintenance phase. The improvements in physical functioning, social functioning,
and obesity-related psychosocial problems were maintained until the end of follow-up.
In study III, the marked weight loss during the programme (10 weeks on VLED and 17
behaviour modification visits during 4 months) was associated with clear decreases in
the OP scale score. Among those completing the weight loss programme (n=100), the
mean(sd) OP scale score was 61.0(24.3) at baseline and 46.3(24.6) at the end of the
group visits (p<0.001). The respective mean(sd) scores were 56.4(24.4) and 42.0(27.3)
for men (p=0.002) and 64.2(23.9) and 49.3(22.3) for women (p<0.001). The effect sizes
were similar for both sexes (0.59 for men and 0.62 for women).
During the programme (Study III) there were clear and significant increases in all the
RAND-36 scales (figure 7). After the group visits, the mean scores on physical scales
were approaching those among healthy Finns. The mean scores on mental scales at
the end of group visits were comparable to those among healthy Finns. The effect
sizes were 0.76 for physical functioning, 0.33 for physical role functioning, 0.35 for
bodily pain, 0.76 for general health, 0.47 for mental health, 0.38 for emotional role
functioning, 0.68 for vitality, and 0.46 for social functioning. The results were similar in
both sexes, but among men the increase in the scores of mental health (76.6(19.2) at
baseline and 80.2(19.1) at the end of group visits, p=0.332) and social functioning
(81.1(23.9) and 86.8(19.3), respectively, p=0.107) were not statistically significant.63
Figure 5. The  RAND-36 scores at baseline pooled data from studies I, III, and IV,
n=140).
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Figure 6. The OP scale scores at baseline (pooled data from studies I and III, n=164).
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In study III, among those with complete 2-year follow-up data (n=67), all the scores on
RAND-36 showed marked improvement at the end of programme (figure 8).
Subsequently, during follow-up after treatment, these improvements started to
diminish. At the 1-year follow-up, physical functioning, bodily pain, general health,
mental health, emotional role functioning, vitality, and social functioning were still ≥ 5
points higher than at baseline. At the 2-year follow-up only physical functioning was still
at a higher level relative to baseline: the sustained increase was 8.9(14.7) points,
effects size 0.36. At the end of programme in study III, 76% of patients reported
improved and only 4% reported worsened health since last year. The respective
proportions at 1-year follow-up were 36% and 25%, and at 2-year follow-up 15% and
31% (note: at 2 years the patients make comparisons with the situation at 1-year
follow-up).
The OP scale reacted differently: the mean score decreased markedly at the end of
programme, and remained at a reduced level for 2-years (figure 9).  The effect size at 2
years was 0.65. At baseline, 60% of patients suffered from severe obesity-related
psychosocial problems, but at 2 years, the proportion had decreased to 36% (figure
10).
Figure 7. The RAND-36 scores at baseline and at the end of group visits in study III
(n=100) and the scores among healthy Finns (n=897, in Aalto A-M et al. 1999). For
comparisons between baseline and end of group visits, the p-value is <0.001 for all,
except physical role functioning (p=0.002).
40 50 60 70 80 90 100
Physical functioning
Physical role functioning
Bodily pain
General health
Mental health
Emotional role functioning
Vitality
Social functioning
mean score
Baseline
End of group
Healthy Finns66
Figure 8. The changes in RAND-36 scores during study III (n=67). P-values in the
table are for each time point compared to baseline.
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Figure 9. The change in obesity-related psychosocial problems (OP scale) in study III
(n=67). P-values in the table are for each time point compared to baseline.
Figure 10. The proportion of patients with mild, moderate, and severe obesity-related
psychosocial problems (OP scale) at baseline and at 2 years in the study III (n=67).
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In study I, the weight loss during the 10-week VLED period correlated to the increasing
scores on physical functioning, general health, vitality (p=0.058), and health-change
since last year (table 16). In study III, the weight loss during the 4-month programme
was correlated to the increasing scores on physical functioning, physical role
functioning, general health, and health-change since last year. With longer follow-up in
these studies (4 months after weight loss programme in study I and 24 months after
programme in study III), the weight loss was correlated to the increase in physical
functioning score and decrease in obesity-related problem score. In study I, there was
also a significant correlation with the increase in health-change since last year. This
association is not apparent in study III, because the patients report their health-change
since the 1-year follow-up visit.
Table 16. The correlation of weight loss and HRQL score changes in studies I, III, IV,
and V. Negative correlation: as the weight decreases the scores increase.
Scale Study I
1 Study I
2 Study
III
3
Study
III
4
Study
IV
5
Study
V
6
Physical functioning -0.449** -0.502*** -0.389*** -0.293* -0.187** ns
Physical role functioning ns ns -0.227* ns ns ns
Bodily pain ns ns ns ns ns -0.307*
General health -0.435* ns -0.321** ns ns ns
Mental health ns ns ns ns ns ns
Emotional role functioning ns ns ns ns ns ns
Vitality -0.334
A ns ns ns ns ns
Social functioning ns ns ns ns ns ns
Health-change since
last year
-0.576*** -0.633*** -0.258* ns -0.260*** ns
Obesity-related problems ns 0.635*** ns 0.519*** - -
Ap=0.058, *p≤ 0.05, **p=≤ 0.01, ***p=≤ 0.001, ns=non significant
Correlation between changes in weight and HRQL scores during: 
110 weeks on VLED
(n=33), 
28-month follow-up (n=33), 
34-month programme (n=87), 
428-month follow-up
(n=63), 
512-month follow-up (n=210), 
612-month follow-up (n=58)
5.4  Testosterone and sexual functions with VLED and
behaviour modification
In study II, the levels of both total and calculated free testosterone increased rapidly
during dieting with VLED and these levels remained increased during the weight
maintenance phase (figure 11). Also SHBG levels increased rapidly during VLED, but
started to decrease towards baseline levels soon after dieting. However, a significant
difference between groups was evident until the end of follow-up. Estrone levels
increased during rapid weight loss and then decreased at the weight maintenance
phase, but estrone levels increased also in the control group and there was no
statistically significant difference between the groups. Estradiol did not change in either
group during the study. Leptin level decreased rapidly during VLED but started to
increase towards baseline level shortly after rapid weight loss. At the end of study, the69
leptin had still increased compared to the change in the control group. There was only
minor fluctuation in the levels of LH, FSH, and prolactin in both groups (available on
request from the author).
Despite the weight loss and increase in testosterone, there was no overall treatment
effect on the scores of erectile function, orgasmic function, intercourse satisfaction,
overall satisfaction, or sexual activity. When the treatment group was divided in three
groups according to the tertiles of weight loss, there were no differences in the changes
of sexual desire score between these groups (data not shown).
Figure 11. The mean change in testosterone (study II). =treatment group (n=19),
=control group (n=19). *=p<0.05, **=p<0.01, and ***=p<0.001 for each follow-up
point compared to baseline.
5.5  HRQL in sibutramine treated obese type 2 diabetics
In study IV, most of the RAND-36 scales did not show statistically significant changes
during the study. However, the scores on physical functioning and health-change since
last year increased in both groups during the study (figure 12), but there were no
statistically significant differences between sibutramine and placebo groups. Larger
weight loss at 12 months was associated with larger increase in the scores of physical
functioning and health-change since last year (table 16).
When both groups were pooled together, the change in HbA1c at 12 months correlated
inversely to the changes in the scores of physical functioning (r=-0.149, p=0.035),
vitality (-0.210, <0.001), mental health (-0.154, 0.026), general health (-0.137, 0.048),
and health-change since last year (-0.165, 0.017); the larger the decrease in HbA1C the
larger the increase in these scale scores.
In the sibutramine group the change in diastolic blood pressure was inversely
associated with the changes in scores of physical functioning (r=-0.20, p=0.04),
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physical role functioning (r=-0.20, p=0.03), emotional role functioning (r=-0.19, p=0.04),
social functioning (r=-0.23, p=0.02), and bodily pain (r=-0.23, p=0.02). In contrast, in
the placebo group there was no associations between changes in HRQL scores and
haemodynamic variables.
Figure 12. The mean changes in RAND-36 a) physical functioning and b) health-
change since last year in study IV (n=102 in sibutramine and 108 in placebo group).
a)      b)
5.6  HRQL after gastric bypass or vertical banded gastroplasty
In study V, all physical scales of SF-36 increased markedly already by the 6-month
follow-up in both groups, and some further increase was evident by the 12-month
follow-up. Similar pattern of change in scores was apparent in mental and social scales
(figure 13). In both groups, the effect sizes are higher in physical SF-36 scales than in
mental scales. However, nearly all the effect sizes for physical and mental scales are
≥ 0.8 indicating large effect. The weight loss at 12 months was associated with the
increase in bodily pain score indicating larger relief in pain with larger weight loss (table
16).
When the results of studies III, IV, and V were compared, the effect sizes for the
changes in SF-36/RAND-36 scores were clearly highest in the study V (figure 14). In
study V, the proportion of patients with the optimal (100) score on SF-36 scales
increased markedly after the operation. At baseline in the GBP group, no patients
reported optimal scores on physical functioning, general health, and vitality. At 12
months, the proportion of patients with optimal scores was 50, 39, and 25%,
respectively. At baseline, the proportion of optimal scores was ≤ 50% in all the SF-36
scales. At 12 months, 92% had optimal physical role functioning, 67% had optimal
bodily pain, 89% had optimal emotional role functioning, and 78% optimal social
functioning.
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Figure 13. The mean scores on SF-36 during the 12-month follow-up (study V).
=gastric bypass, =vertical banded gastroplasty. p<0.001 for all time interactions,
ns for all time x group interactions.
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Figure 14. The effect sizes for the HRQL scores in studies III, IV, and V at the 12-
month follow-up visits (n=102 for sibutramine, 67 for VLED+BM, and 36 for gastric
bypass).
VLED+BM=very-low-energy diet and behaviour modification, PH=physical functioning,
PRF=physical role functioning, BP=bodily pain, GH=general health, MH=mental health,
ERF=emotional role functioning, V=vitality, SF=social functioning
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5.7  HRQL improvement in categories of weight loss
In Study I, the patient population was too small and the follow-up time too short to
examine HRQL changes in categories of weight loss maintenance success. In Study III
HRQL score changes were compared between categories of weight loss maintenance
success (weight gain, 0-9.9% weight loss, ≥ 10% weight loss at 2 years). Clear
differences between these groups were found (figure 15). Surprisingly, weight gain was
associated with improvements in social functioning and obesity-related psychosocial
problems. A 0-9.9% maintained weight loss was associated with improved physical
functioning and obesity-related psychosocial problems. A ≥ 10% maintained weight loss
was associated with a cluster of HRQL benefits (improvement in physical functioning,
physical role functioning, bodily pain, general health, mental health, vitality, and
obesity-related psychosocial problems). For the OP scale scores, the mean(sd)
changes were –6.1(9.8), -13.5(17.3), and –33.9(23.) for weight gain, 0-9.9% weight
loss, and ≥ 10% weight loss, respectively (p=0.002).
In study IV, the HRQL score changes were examined in categories of maintained
weight loss at 12 months (weight gain, and 0-4.9%, 5-9.9%, 10-14.9%, and ≥ 15%
weight loss). In these categories of weight loss significant (≥ 5 point) increases in the
median score were found on physical functioning and health-change since last year
with ≥ 5% maintained weight loss and also on vitality and general health with ≥ 15%
maintained weight loss (figure 16). In this study ≥ 15% maintained weight loss was
needed to create a cluster of HRQL benefits (improvement in physical functioning,
vitality, general health, health-change since last year).74
Figure 15. The changes in RAND-36 scores in categories of weight loss at the 2-year
follow-up  (study III, n=67).
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Figure 16. The median changes in RAND-36 scores in categories of weight loss (study
IV, sibutramine and control groups pooled, n=210).
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5.8  HRQL as a predictor of success in weight loss
maintenance
In Study III most HRQL scores at baseline were not correlated to the maintained weight
loss at 2 years, only social functioning showed inverse correlation (r=-0.277, p=0.032);
better social functioning at baseline was correlated to larger maintained weight
reduction at 2 years. The HRQL score changes during the 4-month programme (with
mean(sd) weight loss of 12.5(5.6)%) did not correlate to weight loss at 2 years, except
for the obesity-related psychosocial problems with direct association (r=0.357,
p=0.010); the larger the decrease in OP scale score during treatment the larger the
maintained weight loss at 2 years.
In Study IV (with the sibutramine and placebo groups pooled together), several of the
baseline RAND-36 scores and score changes during the first 3 months of the study
(when most weight loss occurred) were correlated to weight loss at 12 months. In a
stepwise backward multiple regression, baseline emotional role functioning (β  0.21,
p=0.006), social functioning (β  0.22, p=0.008), and mental health (β  -0.26, p=0.003)
were associated with the 12-month weight loss. Some score changes during the first 3
months of study were associated with 12-month weight loss: physical functioning (β
0.23, p=0.001), emotional role functioning (β  0.18, p=0.019), vitality (β  0.33, p<0.001),
and social functioning (β  -0.14, p=0.068).
Based on these stepwise multiple regression analyses, the RAND-36 scale
scores/score changes with positive correlation to 12-month weight loss result were
selected for a cluster analysis. These four HRQL variables were dichotomised with
clinically meaningful cut-off points (baseline emotional role functioning ≥ 75=1 and
<75=0; baseline social functioning ≥ 80=1 and <80=0; 3-month change in physical
functioning >0=1 and ≤ 0=0; 3-month change in vitality >0=1 and ≤ 0=0). The mean(sd)
weight loss at 12 months was examined in subgroups created by the sum of these
dichotomised HRQL variables (figure 17): the mean weight loss at 12 months
increased linearly with increasing cluster. Those with good emotional role functioning
and good social functioning at baseline and improvement in physical functioning and
vitality during the first 3 months of study achieved the largest maintained weight loss at
12 months (9.0 (8.1)% of baseline weight).
In study V, the mental health score at baseline was associated with the weight loss
result at 12 months (r=-0.366, p=0.005): the higher the score on mental health at
baseline, the larger the weight loss result at 12 months. No other associations between
baseline HRQL scores and weight loss result were found in study V.77
Figure 17. The weight change at 12 months in cluster groups defined as the sum of the
following four HRQL variables (baseline emotinal role functioning ≥ 75=1 and <75=0;
baseline social functioning ≥ 80=1 and <80=0; 3-month change in physical functioning
>0=1 and ≤ 0=0; 3-month change in vitality >0=1 and ≤ 0=0). The summary box plot
presents the median, quartiles, and extremes. P<0.001 for One-way ANOVA.
Sibutramine and control groups pooled, completers population.
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6 DISCUSSION
6.1  Patients and methods
The purpose of these studies was to increase knowledge on the associations between
HRQL and intentional weight loss in different clinical populations following different
treatment procedures. In studies I and II, most of the men were recruited by a
newspaper add, only a few were referred from a health-care centre. However, the aim
was to include men with obesity-related chronic conditions. Previous non-surgical
weight loss studies reporting HRQL data have usually used samples with lower mean
BMI and less comorbidity. They have mostly included women, whereas in studies I-V,
the proportion of men was 41%. The methods and criteria for patient selection resulted
in clinically representative samples in all studies. The results of these studies can
readily be generalised to patient groups entering weight loss treatment in other health-
care units. The results may not be generalised to groups of people losing weight in
other settings (e.g. by themselves, in commercial weight loss programmes, in peer-
support groups).
The aim was to provide scientifically sound data. Some of the previous studies were
randomised controlled trials, but often there was no difference in weight loss between
treatment arms and HRQL results are reported in a pooled sample (Karlsson et al.
1994, Fontaine et al. 1999). Those randomised trials, that have produced a difference
in weight loss between groups and reported differences in HRQL responses, have
been very short in duration (12 weeks) and have not included any follow-up after
treatment (Rippe et al. 1998, Nieman et al. 2000). In studies III and V there was no
control group, which limits the conclusions on a causal link between therapy and HRQL
changes. On the other hand, study III had a relatively large sample size and a long
follow-up time: it was possible to examine the association between success in long-
term weight maintenance and HRQL changes (dose-response). In study V the weight
loss after surgery was substantial allowing HRQL scores changes to vary more. It can
also be argued, that it is unethical to use a control group with no intervention in a long-
term study among a patient population with severe obesity and high level of
comorbidity.
There are several reasons why HRQL measurement is useful in weight loss studies.
Many HRQL domains are affected by obesity, mainly physical functioning, but also
mental and social domains. There are numerous obesity-related problems that become
more severe with increasing weight. Therefore, measuring weight as the only outcome
in weight loss trials is simply insufficient. The questionnaires used in these studies are
well known and well characterised. The studies in this thesis include a generic
measurement and studies I, II, and III include also disease-specific instruments.
Combining generic and obesity-specific questionnaires enables a comparison with the
general population and increases sensitivity to disease-specific change in areas of
most concern to the obese individuals. HRQL was measures at baseline, repeatedly
during follow-up, and again at study termination. Previous experience of repeated79
(≥  three time points) HRQL-measurement is scarce and includes mostly surgical weight
loss studies. Repeated measurement is feasible for three reasons: First, it is essential
in order to segregate the transient and maintained effects of weight loss. Second,
evidence of questionnaire reproducibility is obtained when there are only minor
changes in the control group without intervention. Third, evidence of questionnaire
validity is gained when the direction of changes in the intervention group meets
expectations. Well-known and validated generic questionnaires with the population
reference values available measured HRQL in all studies. The original Swedish OP
scale was translated and adapted to Finnish according to the current guidelines
(Bullinger et al. 1998). A clear limitation is the lack of obesity-specific questionnaires in
studies IV and V. Diabetes-specific questionnaires were not included in any of the
studies. Obesity- and diabetes-specific HRQL questionnaires might be more sensitive
to changes in weight and/or glycaemic control than the generic measure used here.
The aim was to design sufficiently powered studies with minimum risk of falsely non-
significant changes. However, since none of the studies’ sample sizes were calculated
based on the properties of HRQL questionnaires, some of the observed changed may
be falsely non-significant, especially in studies I and II with the smallest sample size.
Small sample size led to potential bias owing to the uneven distribution of some
variables (especially comorbidity) possibly affecting HRQL. Small sample size might
not reveal minor yet important effects. In order to allow the reader to draw his/her own
conclusions on the results, HRQL data for all the measurement points is reported, and
also the near significant p-values are presented.
The dropout rates (11-53%) in studies I-V were similar or even lower than dropout rates
in previous weight loss studies. The data was analysed both in the completers and
intention to treat –populations in the randomised trials (studies I, III, and IV). There
were no significant differences in the results of these analyses, which further validates
the results. In studies III and V only the completers' data was analysed. For the
longitudinal HRQL data we used the general linear model, repeated measure
procedure. The magnitude of change was expressed as the effect size, which
facilitates the comparison of results in different studies and different questionnaires.
Repeated measurement of multiple outcomes poses the possibility of statistically
significant differences without true treatment effect. Therefore, the tentatively significant
results (p-values 0.05-0.10) merely indicate possible treatment effects and need to be
explored in future studies with larger populations. All the changes in HRQL scores must
be viewed against the available knowledge on the minimum clinically significant
change.
6.2  HRQL among patients entering weight loss treatment
In observational population based studies, increasing degree of obesity has been
associated with impaired HRQL, especially physical functioning. Morbid obesity
(Sullivan et al. 1993), co-morbid conditions (Doll et al. 2000), eating disorders
(Stunkard and Sobal 1995), and pain (Barofsky et al. 1997) have adversely affected
mental HRQL. Sex, level of obesity, treatment seeking status, and modality of future80
treatment have all been associated with obesity-specific HRQL: the morbidly obese
women seeking for surgical weight loss treatment have the lowest HRQL scores
(Kolotkin et al. 2002). Some previous surgical studies have reported baseline SF-36
scores. The largest impairment seems to be in physical scales of SF-36 when surgical
cases are compared to the population reference (Dixon et al. 2001, Dittmar et al.
2003), but among heavier patient groups also mental scales are deteriorated (Choban
et al. 1999). In this thesis, the pooled data from studies I and III showed that the
mean(sd) score of OP scale was 60.1(24.3) and well over half of patients reported
severe to extreme impairment in psychosocial functioning. At baseline, the patients
scored significantly lower in all the scales in RAND-36 compared to the scores in the
general population.
Sex: When the baseline data from studies I, III, and IV was pooled, men had slightly
better RAND-36 scores on all the scales, especially on physical functioning and vitality.
Women also reported more obesity-related psychosocial problems in everyday life.
This finding is in accordance with the previous studies among the obese seeking
weight loss: women have reported worse current health, mental well-being,
psychosocial problems (Sullivan et al. 1993, Karlsson et al. 2003), and obesity-related
problems in physical function, self-esteem, sexual life, public distress, and work
(Kolotkin et al. 2002). Also the scores on feelings and beliefs related to obesity, and
scores on obesity symptoms have been worse among women (Patrick et al. 2004).
BMI: Despite of the highly selective patient population, higher BMI was associated with
deteriorated RAND-36 and OP scale scores (studies I, III, and IV, pooled data). In
previous studies among obese patients seeking weight loss, increasing degree of
obesity has been associated with decreasing HRQL scores (Sullivan et al. 1993,
Fontaine et al. 1996, Kolotkin et al. 2002, Karlsson et al. 2004, Patrick et al. 2004). In
the surgical patient groups, the association between baseline BMI and HRQL has
varied. Preoperative BMI was associated with poor physical health, but not mental
health (Dixon et al. 2001). In another study, the degree of preoperative BMI (mean 51
and range 38 to 85 kg/m
2) was not associated with SF-36 scores (Choban et al. 1999).
The differences in these associations probably reflect the differences in BMI distribution
between study populations: the surgical groups are by far the heaviest patient groups,
therefore the discriminatory abilities of a generic questionnaire may diminish.
Age: The higher the age, the higher the OP scale scores indicating more obesity-
related psychosocial problems. Age was also associated with generic HRQL scores in
a surprising way: the older the patients, the higher the scores on mental health and
vitality. There were no other clear associations between age and RAND-36 scores
(studies I, III, and IV, pooled data). One previous study has reported decreasing scores
on obesity-related feelings, beliefs and symptoms with increasing age (Patrick et al.
2004).
Treatment modality: Only one pervious study has examined HRQL scores in different
treatment modalities: the gastric bypass patients had the worst HRQL, followed by day
treatment patients, followed by participants in outpatient weight loss81
programmes/studies, followed by participants in clinical trials who had the best HRQL
(Kolotkin et al. 2002). In studies I-V, the scores for the generic questionnaires were
lowest among the patients entering either surgery or VLED and behaviour modification,
and highest among those entering the weight loss drug trial. The baseline scores in
study V should not be directly compared to those in other included studies due to
differences in algorithms, translations and population reference values. Despite a
specific study population comprising obese type 2 diabetics, the HRQL scores at
baseline were on some scales even better than in the Finns with no chronic diseases.
This may be due to strict inclusion criteria, relatively good metabolic control, and no
significant diabetic complications at baseline. However, the effects of obesity on HRQL
may be one of the most important factors that determine the willingness to lose weight
and the choice of treatment method.
Comorbidity: In population based observational studies, the HRQL scores have been
lower among the obese with comorbidity than among healthy obese (Doll et al. 2000).
In the SOS-study, somatic morbidity (joint symptoms, angina pectoris, bed days in
hospital) and previous psychiatric morbidity were associated with poor current health
perception (Sullivan et al. 1993).  Another study showed, that obese patients with pain
had significantly lower HRQL scores than those not reporting pain (Barofsky et al.
1997). Studies examining the associations with type 2 diabetes and HRQL are scarce.
In cross-sectional studies (Weinberger et al. 1995, Anderson et al. 1997) glycaemic
control has been associated with HRQL measured by diabetes specific questionnaires,
but not with the generic SF-36. However, diabetic complications (especially
macrovascular diseases) and other comorbid illnesses seem to deteriorate HRQL
measured by SF-36 among type 2 diabetics (Jacobson et al. 1994, Clasgow et al.
1997, Hänninen et al. 1998, Hirsch et al. 2000, Woodcock et al. 2001).
6.3  HRQL changes during weight loss and weight loss
maintenance
Many studies examining HRQL in morbidly obese patients treated with bariatric surgery
have been published showing dramatic and long-term improvement in initially poor
HRQL (table 11). Knowledge on HRQL in other patient populations is limited and the
HRQL changes associated with weight loss induced by VLED and behaviour
modification have not been published before.
There are only two previous randomised controlled trials that have compared active
treatment arms against a control group receiving no intervention. In these trials with
life-style intervention the weight loss during treatment has been less than 10 %,
however, the scores on physical functioning, vitality, and mental health (Rippe et al.
1998) and psychological general well-being improved (Nieman et al. 2000). Both of
these studies, however, were very short in duration (12 weeks), included only women,
did not include any follow-up after treatment, and did not include any obesity-specific
instruments. In studies I and III, the rapid weight loss with VLED was associated with
clear increases in all HRQL measures. Poor scores on physical RAND-36 scales were
improved closer to the level observed in the healthy general population. The scores on82
mental health scales reached the level of the reference population, in some cases the
scores of our patients exceeded those of the general population. The scores on OP
scale were reduced indicating less obesity-related problems. In study I the scores on
RAND-36 and OP scale showed very little changes in the weight stable control group.
Are the clear improvements in HRQL sustained after the active weight loss period is
over and the patients shift over to the weight maintenance phase? The advantage of
the studies in this thesis is the relatively long follow-up periods (nearly 6 months after
treatment in studies I and II, two years after treatment in study III, and one year in
studies IV and V). This segregates the short and long-term effects of weight loss
treatment on HRQL. During longer follow-up in studies I and III, most of the HRQL
scores started to return toward baseline levels. Some of this effect is evident right after
the VLED-period in study I, especially in the mental scales on RAND-36. In study III, all
the RAND-36 scores inversely follow the regain in weight.
One previous study has examined the effects of intentional weight loss and subsequent
weight regain on HRQL (Engel et al. 2003). Weight loss (mean 19%) was linearly
associated with improvement in IWQOL-Lite scores, and weight regain (mean 10%)
was linearly associated with deterioration in IWQOL-Lite scores. The HRQL score
changes in studies I and III seem to follow this pattern, too. The OP scale was the only
exception; it showed sustained decrease in scores despite of the weight regain over
the two-year follow-up in study III. This unique pattern of response may be a cause of
the patients’ intra- and interpersonal changes after the marked weight loss and being
exposed to group support and behaviour modification techniques.
At two years, only physical functioning and obesity-related psychosocial problems were
still improved relative to baseline: the effect size was 0.36 (small) for physical
functioning and 0.60 (moderate) for obesity-related problems. There are few previous
life-style intervention studies with long follow-up, which have shown improvement in
functioning status and mental well-being over two years (Karlsson et al. 1994), in some
physical and mental scales on SF-36 over one year (Marchesini et al. 2002), and in
general health and vitality over one year (Fontaine et al. 2004). These studies,
however, differ in patient selection, weight loss intervention, achieved weight loss, and
success in weight loss maintenance.
It seems clear that intentional weight loss produces HRQL benefits in the short term. In
the longer term, at least physical functioning and obesity-related psychosocial
problems seem to improve on average. Experience from longer term weight loss
studies with life-style intervention are scarce and well-designed studies combining
generic and obesity-specific instruments are urgently needed in order to evaluate the
sustained HRQL effects of weight loss and subsequent weight maintenance.83
6.4  Weight loss and sexual functions
Study II showed, that despite of marked weight loss (14%) and increase in serum free
testosterone (47.4 pM increase from the baseline level of 201.3 pM, normal range 100-
300 pM among 41-50 year old men) there were no significant changes in the sexual
function scores. Previous studies on the effect of intentional weight loss on
testosterone level have showed increase (Stanik et al. 1981, Pasquali et al. 1988,
Strain et al. 1988, Bastounis et al. 1998, Pritchard et al. 1999, Niskanen et al. 2004), no
change (Hoffer et al. 1986, Leenen et al. 1994, Kraemer et al. 1999), and decrease in
testosterone (Klibanski et al. 1981). These contradicting results are probably due to
differences in study populations, especially in age, metabolic profile, degree of obesity
and amount of weight loss. The differences in time points of hormone determinations
(during active weight loss or during weight maintenance) may also contribute to the
varying findings. However, most of the previous trials show an increase in testosterone
level after weight loss. Study II is the first randomised clinical trial with a weight stable
control group and the results confirm this finding.
There is limited information on the associations between sexual functions and obesity
in the general population. Only a few case-reports of decreased libido and impotence in
extremely obese men have been published (Blum et al. 1988), but no relationship
between obesity and abnormalities in libido were apparent in a larger study (Strain
1982). Impotence is strongly related to age, with an estimated prevalence
 of 2% at age
40 years rising to 25-30% by the age of 65 (Furlow 1985). In the Finnish elderly general
population, the prevalence of impotence was 25% among 60 year-olds and 49%
among 70 year-olds (Koskimäki et al. 2000). Impotence is even more common among
men with diabetes (McCulloch et al. 1980, Wändell and Brorsson 2000). Most strongly
associated with impotence were age, treatment with insulin or oral hypoglycaemic
agents, and microvascular complications. (McCulloch et al. 1980). Among diabetics
with poor metabolic control, weight loss and related metabolic have improved sexual
functions (Fairburn et al. 1982).
In study II, the fact that sexual functions did not improve with weight loss and increase
in serum testosterone level may be due to several reasons. First, the men in this study
were relatively young with a mean age of 46-47 years and the baseline scores on
erectile function were quite high; impotence is more common among older men.
Second, type 2 diabetes (over 5 years from the diagnosis) was an exclusion criteria,
thus only a few men in study II had diabetes; impotence is more common among
diabetics with poor metabolic control and vascular/neurological complications. One
previous study with surgically induced weight loss has reported improvement in sexual
functions (Larsen 1990). Some (Rand et  al. 1982, Globe et al. 1986), but not all (Neill
et al. 1978) studies have reported improvement in marriage after weight loss surgery. A
more recent study among the patients’ partners reported that 59% of partners had
experienced improvement in partnership and 45% improvement in sexual relationship
after the patients had laparoscopic gastric banding (Kinzl et al. 2003). It is impossible to
conclude, whether these improvements were due to weight loss, increase in
testosterone level, or improvement in glucose metabolism. Based on study II, it can be84
concluded that among non-diabetic obese men intentional weight loss and associated
increase in serum testosterone levels do not improve sexual functions. Future studies
should further examine the effects of weight loss on sex hormones and sexual
functions among obese subjects with type 2 diabetes.
6.5  HRQL and sibutramine
Study IV was a randomised placebo-controlled trial on the HRQL effects of sibutramine
among obese patients with type 2 diabetes. There is no previous RCT on the HRQL
effects of a weight loss drug. Two previous studies have reported data on the
associations of weight loss and HRQL among obese patients using phentermine-
fenfluramine (Kolotkin et al. 2001b) and an unknown weigh loss product (Patrick et al.
2004). In these studies the marked weight loss (18% with phentermine-fenfluramine
and 38.4 kg with the unknown product) was associated with clear improvement in
obesity-related HRQL. These studies did not include generic HRQL instruments.
One previous report included a pool of four randomised placebo-controlled trials of
sibutramine and examined the association between weight loss and HRQL measured
by SF-36 and IWQOL-Lite (Samsa et al. 2001). In the short- and medium-term (8-28
weeks), there were improvements in some mental but mainly physical scales of the
questionnaires. At the one-year follow-up, there were statistically significant
associations between weight loss and increases in the scores on physical functioning,
physical role functioning, and vitality (SF-36) and of mobility and activities of daily life
(IWQOL-Lite). These scales showed a dose-response pattern with larger weight loss
associated with greater improvements in HRQL. The study, however, did not report
weight loss result of HRQL changes in sibutramine and placebo groups separately;
therefore conclusions on the HRQL effects of sibutramine cannot be drawn.
In study IV at the one-year follow-up, the sibutramine groups lost on average 7.3% and
the placebo group 2.4%. Both groups reported an increase in the scores of physical
functioning and health-change since last year and these improvements were correlated
to weight loss. Despite the significantly greater weight loss with sibutramine, there were
no significant differences in HRQL responses between the groups. The placebo-
subtracted weight loss in the sibutramine group was approximately 5 kg less. Based on
previous studies, this amount of weight loss has been associated with improvements in
SF-36 scores (Rippe et al. 1998, Fontaine et al. 1999, Samsa et al. 2001, Fontaine et
al. 2004) and a significant difference in HRQL responses between groups was
expected in study IV, too.
Several reasons may explain why there was no difference in HRQL changes between
the sibutramine and the placebo group in study IV. Despite a specific study population
comprising obese type 2 diabetics, the HRQL scores at baseline were on some scales
even better than in the healthy Finns. This may be due to strict inclusion criteria of a
drug trial: the patients had relatively good metabolic control, no significant diabetic
complications, and no significant comorbidity at baseline. Compared to another
intervention trial (Goddijn et al. 1999) with type 2 diabetics in poor metabolic control at85
baseline (mean HbA1c 10.4%) our patients scored higher (≥  5 points) on several
RAND-36 scales, namely physical functioning, physical role functioning, emotional role
functioning, mental health, and especially vitality. This, too, indicates that the baseline
HRQL was relatively good among our patients. This may lead to ceiling effects or to
non-representativeness of the study population. The therapeutic effect of participating
in a trial including behaviour modification may explain some of the HRQL improvement.
In addition, obesity- and diabetes-specific HRQL questionnaires are more sensitive to
changes in weight and/or glycaemic control than the general measure used here.
Adding a specific measure might have revealed clinically important HRQL effects of
sibutramine and/or weight loss. Unfortunately, disease-specific questionnaires were not
available in Finnish during the study.
Another possible explanation of the results in study IV is, that some other factor
associated with the use of sibutramine prevents the HRQL benefits of the larger weight
loss. In synergy, none of the randomised placebo controlled trials on sibutramine
among type 2 diabetics have shown benefits in glycaemic control despite of the
superior weight loss (table 6). Sibutramine has several adverse effects; the most
common are dry mouth, anorexia, and insomnia. Sibutramine also interacts with the
sympathetic nervous system: common adverse effects are an increase in blood
pressure and pulse. These adverse effects may influence HRQL perceptions. In study
IV in the sibutramine group, the change in diastolic blood pressure was inversely
associated with the changes in scores of physical functioning, physical role functioning,
emotional role functioning, social functioning, and bodily pain. In contrast, in the
placebo group there ware no associations between changes in HRQL scores and
haemodynamic variables. Systolic blood pressure and pulse were not associated with
HRQL scores in either group. We were not able to compare the HRQL changes among
those with and without adverse effects, but future pharmacotherapy trials should
address the possible negative effect adverse events have on HRQL.
The conclusion on study IV is that despite the superior weight loss, sibutramine did not
produce HRQL benefits over placebo among obese type 2 diabetics losing weight. This
question of HRQL effects should be repeated in future sibutramine trials. In general,
future pharmacotherapy trials should be carried out in representative patient
populations and with both generic and obesity/diabetes –specific HRQL instruments.
6.6  HRQL after GBP or VBG
The results showed, that both GBP and VBG resulted in marked weight loss, that was
well-sustained up to the one-year follow-up (34% and 26% for GBP and VBG,
respectively). During the study all SF-36 scores increased markedly in both groups, but
there were no differences between groups. The effect sizes were 0.8-1.7 for the
physical scales and 0.4-1.2 for mental scales indicating mostly large positive effect. At
the end of follow-up, the mean scores on SF-36 were similar to the Swedish normal
weight general population and ≥ 50% of patients reported optimal HRQL in physical
functioning, physical role functioning, bodily pain, emotional role functioning, and social
functioning.86
One previous study (Hell et al. 2000) compared gastric bypass, vertical banded
gastroplasty, and laparoscopic gastric banding prospectively with respect to HRQL
(BAROS). No generic measure was included. The follow-up time was 20 months in the
VBG and 40 months in the GBP groups. The results favoured gastric bypass: this
operation was superior in weight loss and improvement in quality of life. The pattern of
side effects between GBP and VBG is different (Colquitt et al. 2003). VBG is more
likely to give vomiting, whereas GBP causes dumping and sometimes diarrhoea. If the
adverse effects and specific HRQL responses differ between procedures, a difference
in generic measures might be expected. However, in our study, HRQL improved after
both GBP and VBG. These findings don’t necessarily contradict each other, since there
are differences in HRQL instruments. SF-36 is a generic instrument and therefore
possibly not as sensitive to specific issues related to morbid obesity and bariatric
surgery. However, using a well-known and validated generic instrument allows greater
generalisation and comparability between patient populations and interventions. Future
studies should combine generic measurements with instruments specific to both
obesity and bariatric surgery.
Weight loss surgery results in much larger weight loss than any other method. This
weight loss is also maintained much longer than with any other method. Do the HRQL
benefits last as long? Some studies have reported that after initial increase there is a
decrease in HRQL scores during long-term (≥ 2 years) follow-up. VBG produced
significant improvement in the scores of Nottingham Health Profile I and II during the
first year. During the second year the HRQL scores showed some decrease in spite of
patients having no weight regain (Van Gemert et al. 1999). Physical well-being, mood,
physical performance, coping with illness, social support, and perceived health have all
markedly improved during the first 6 months after VBG, but there was some tendency
for the scores to decrease during further follow-up (Sabbioni et al. 2002). In the SOS-
study, large short-term improvements were followed by a slight to moderate long-term
decline in HRQL scores, especially among those with modest weight loss (Karlsson et
al. 1998, Karlsson et al. 2003). This pattern was most evident in the scales for
emotional well-being. In our study, there were clear improvements in all SF-36 scales
during the first 6 months postoperatively and in general the scores continued to
increase during 6 to 12 months of follow-up. Further follow-up will reveal the pattern of
weight and HRQL responses in our surgical patient population.
One obvious limitation of study V is the design: there was no randomisation into
treatment groups and there was no weight stable control group. Caution is therefore
advisable when interpreting these results as proof of equality between GBP and VBG.
Another limitation of this study is the lack of obesity, diabetes, or surgery specific
questionnaires. Specific instruments may yield important effects of surgical weight loss
procedures. They also may bring out some clear differences between procedures. The
third limitation is the short follow-up time. Longer follow-up with repeated HRQL
measurement is required to confirm the benefits of bariatric surgery.87
6.7  Are HRQL changes related to weight loss?
Life-style changes, pharmacotherapy, and surgical procedures lead to weight loss, but
that is not all. Simultaneously with weight loss metabolism improves and the symptoms
and findings of obesity-related diseases improve. Regardless of weight loss method,
treatment programmes always include attempts to increase physical activity. All of
these factors may influence HRQL responses to weight loss treatment. Most of the
previous studies on intentional weight loss and HRQL have reported a positive
association (the larger the weight loss the larger the improvement in HRQL), but there
are contradicting results. A one-year follow-up reported that general health and vitality
improved regardless of whether the initial weight loss was maintained or not (Fontaine
et al. 2004). Another study showed that the OWLQOL and WRSM scores increased
both in weight losers and in weight gainers (Patrick et al. 2004). Some surgical studies
have reported that after initial increase there is a decrease in HRQL scores during
long-term follow-up (Karlsson et al. 1998, Karlsson et al. 2003, Van Gemert et al. 1999,
Sabbioni et al. 2002).
In the studies I-V, not all the HRQL changes were correlated to weight loss (table 16).
In study III, during the 4-month weight loss programme and a mean weight loss of over
10%, only the increases in physical functioning, physical role functioning, general
health, and health-change since last year were significantly correlated to weight loss,
although all the measures improved during treatment. During further follow-up,
improvement in physical functioning (studies III and IV), bodily pain (study V), health-
change since last year (study IV), and obesity-related psychosocial problems (study III)
were significantly correlated to weight loss. The correlation coefficients, however, were
quite low.
Other factors than weight loss may play a role. In study III, the patients reported
increases in physical activity over the 2-year follow-up, which may have contributed to
the improvement in physical functioning scores. In studies III, IV, and V, the
improvement of glycaemic control with loss of hyperglycaemic symptoms may
contribute to the HRQL changes. One previous randomised intervention study showed
that regular phone-contacts with the patients improved glycaemic control but did not
induce any improvement in HRQL measured by SF-36 (Weinberger et al. 1995).
Another study showed that by achieving good glycaemic control (HbA1c from 10.4% to
7.8% during one-year follow-up) and by losing hyperglycaemic symptoms, the patients
gained HRQL benefits especially in physical functioning, vitality, and health-change
since last year (Weinberger et al. 1994).  In our population, the preliminary analyses of
the metabolic data suggest that the glycaemic control improved among type 2 diabetics
after the marked weight loss with VLED (study III, data not shown). This may have an
effect on the HRQL changes documented in this study, but the population was too
small to allow subgroup analyses comparing the HRQL changes between those with
and without comorbidity (diabetes, obstructive sleep apnoea, degenerative joint
disease, etc.). In study IV, the improvement in glycaemic control was associated with
slight improvement in physical functioning, vitality, mental health, general health, and
health-change since last year.88
In addition to correlation analyses, the patterns of weight and HRQL changes can be
compared. Is there a mirror-effect: as weight decreases the scores improve, and vice
versa? In this thesis, improved HRQL was not always associated with weight loss. In
study III, all the mental and most of the physical RAND-36 scales followed the weight
curve inversely: as weight decreased the scores increased, but as the weight was
regained, the scores decreased back to the baseline level. However, it is evident that
obesity-related psychosocial problems and physical functioning stayed at a more
improved level than was expected by the pattern of weight change. The OP scale score
and social functioning score improved also among those with weight gain since
baseline. This study is unable to examine reasons for this phenomenon, but intra- and
interpersonal changes triggered by treatment, weight loss, group support, and
subsequent weight maintenance period may hold the answer. However, it is of
importance that after treatment HRQL seems not to deteriorate among those
unsuccessful at weight loss maintenance.
In conclusion, some of the HRQL scores follow the pattern on weight change during
and after treatment, but weight loss may be only one of the factors that affect HRQL
responses. More RCTs are needed to answer the question. Future studies should
control for other factors, such as physical activity and glycaemic control, which may
influence the HRQL responses. Also, the therapeutic effect of participating in a
treatment programme may explain some HRQL improvement.
6.8  How much weight loss is needed to improve HRQL?
It is generally accepted, that 5-10% of weight loss is enough to reduce the risk of
obesity-related diseases and to improve obesity-related metabolic disturbances. This is
the amount of weight loss that most clinical guidelines recommend to the obese patient
(Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and
Obesity in Adults 1998, Mustajoki et al. 2002). Is 5-10% of weight loss enough to
improve everyday HRQL? Studies III and IV with the longest follow-up and the widest
variance in weight loss result tried to answer this question.
The minimal clinically important difference for the RAND-36 is 3-5 points (Samsa et al.
1999, Hays and Morales 2001) and for the OP scale 4 points (Karlsson et al. 2003).
When changes in questionnaire scores are examined in categories of weight loss, the
category in which the score change reaches the MCID determines the amount of
weight loss needed to produce a meaningful improvement in HRQL.
A previous study pooling data from four placebo-controlled sibutramine trials (Samsa et
al. 2001) reported the changes in SF-36 and IWQOL-Lite scores in categories of weight
loss. Despite of pooling four studies the sample size was still rather small. In the long-
term (52 weeks), a 0-5% weight loss was associated with 8 point increase in physical
functioning and a 5 point increase in health-change since last year. A 5-10% weight
loss was associated with increases in physical functioning (11 points), physical role
functioning (8 points), vitality (5 points), and health-change since last year (11 points).89
Over 10% weight loss was associated with similar, but larger improvements, and also
increases in general health (7 points) and bodily pain (3 points). The minimal clinically
important difference for SF-36 scales is estimated at 3-5 points. The MCID for IWQOL-
Lite has not been published, but there was a statistically significant improvement in the
scores for mobility and activities in daily living across the weight loss categories.
Another study with an unknown weight loss product (follow-up 50-83 weeks) showed,
that the changes in OWLQOL and WRSM scores were improved across increasing
categories of weight loss, but the minimal clinically important difference of these
questionnaires is still unknown. Without the knowledge on MCID, it is impossible to
estimate the amount of weight loss needed to improve the patients’ HRQL.
In study III at the two-year follow-up, a 0-9.9% maintained weight loss was associated
with improved physical functioning and obesity-related psychosocial problems. A ≥ 10%
maintained weight loss was associated with a cluster of HRQL benefits (improvement
in physical functioning, physical role functioning, bodily pain, general health, mental
health, vitality, and obesity-related psychosocial problems). In study IV at the one-year
follow-up, ≥ 5% maintained weight loss was associated with improvement in physical
functioning and health-change since last year, but ≥ 15% maintained weight loss was
needed to improve physical functioning, vitality, general health, health-change since
last year.
Based on these results among the obese patients in clinical studies, moderate weight
loss is associated with improvement in physical functioning and obesity-related
problems, but over 10-15% of weight loss is needed to create a cluster of HRQL
benefits.
6.9  Does HRQL predict success in weight loss maintenance?
Previous qualitative research has concluded, that “initial well-being seemed to predict
weight loss maintenance”, but “permanent behavioural changes were required for
sustainability of weight loss” and “since adequate improvements in well-being and
quality of life were seldom experienced after weight loss, regain was understandable”
(Sarlio-Lähteenkorva 2001). Various factors have been suggested as predictors of
weight loss success (age, education, social support, realistic expectations, diet
compliance, etc.). However, the patients report that improvement in well-being is often
the primary reason to seek weight loss (Hankey et al. 2002). It is possible, that pre-
treatment HRQL or changes in HRQL during weight loss predict outcome success:
those experiencing improvements in HRQL may be resistant to other factors favouring
weight regain.
A study from Sweden reported that the baseline SIP score predicted relapse: the more
initial dysfunction, the greater the amount of weight regain during follow-up (Karlsson et
al. 1994). Studies III, IV, and V examined the association baseline HRQL scores and
success in weight loss maintenance. In Study III, the score on social functioning
showed inverse correlation; the better social functioning at baseline the larger
maintained weight reduction at 2 years. In study V, the mental health score at baseline90
was associated with the weight loss result at 12 months; the higher the score on mental
health at baseline the larger the weight loss result at 12 months.
No previous studies have reported the predictive properties of HRQL changes early
during treatment: if weight loss is associated with HRQL gains, is the weight loss more
likely to be sustained? In study III, the larger the decrease in obesity-related
psychosocial problems during the four-month treatment the larger the maintained
weight loss at 2 years. In study IV, the change in bodily pain score during the first 6
months after operation was inversely associated with the weight loss result at 12
months: those experiencing most release in bodily pain lost the most weight.
In Study IV, several of the baseline RAND-36 scores and score changes during the first
3 months of study (when most weight loss occurred) were correlated to weight loss at
12 months. The cluster analysis showed that those with good emotional role
functioning and good social functioning at baseline and improvement in physical
functioning and vitality during the first 3 months of study achieved the largest
maintained weight loss at 12 months.
It seems, that high scores on mental scales (mental health, social functioning,
emotional role functioning) at baseline may predict success in weight loss
maintenance. This poses a serious question: is long-term weight loss maintenance
possible to only those with good mental health and social functioning? Improvement in
HRQL scores during weight loss may also prove to be useful in predicting long-term
outcome. HRQL probably has differing predictive properties depending on the type of
population and the type of intervention, and future studies should examine the
association of HRQL and weight loss maintenance.91
7 SUMMARY  AND  CONCLUSIONS
This dissertation includes clinical studies on intentional weight loss and HRQL among
obese patients. HRQL was measured with SF-36/RAND-36 and OP scale. The total
number of patients was 474, 41% of them were male, the mean age was 48.4 years,
and the mean BMI was 38.7 kg/m
2.
Studies I and II were based on a randomised clinical trial with 19 obese (mean BMI
39.3 kg/m
2) men in the treatment arm (10 weeks on VLED and 4 months of behaviour
modification) and 19 men (39.4(3.7) kg/m
2) in the control arm with no intervention. The
study duration was eight months, the follow-up time after treatment was four months.
The dropout rate was low: 3 men in the treatment groups and 2 men in the control
group. The mean(sd) weight loss at the end of follow-up was 13.9(7.8)% in the
treatment group, the control group was weight stable. During the treatment, there was
transient improvement in many HRQL scales. The improvement in physical functioning,
social functioning, and obesity-related psychosocial problems was maintained until the
end of follow-up. Despite the weight loss and increase in serum testosterone level, the
questionnaire (IIEF and SAS) scores on sexual functions did not change.
Study III included 126 obese (mean BMI 39.3 kg/m
2) outpatients entering the treatment
programme identical to studies I and II. The follow-up time in study III was two years
after the treatment. A hundred patients completed the treatment programme and 67
patients completed the two-year follow-up. The mean(sd) weight loss among
completers was 12.5(5.6)% at the end of treatment programme, 6.0(7.1)% at one year,
and 2.6(7.5)% at two years. All the HRQL scales improved markedly during the
treatment  programme, but as weight was regained the scores started to decrease. At
two years there was maintained improvement in physical functioning and obesity-
related psychosocial problems. A ≥ 10% maintained weight loss was associated with a
cluster of HRQL benefits (improvement in obesity-related psychosocial problems,
physical functioning, physical role functioning, bodily pain, general health, mental
health, and vitality).
Study IV was a randomised placebo-controlled trial of sibutramine (15 mg daily) in
obese (mean BMI 36 kg/m
2) patients with type 2 diabetes. The ITT-population
comprised 232 patients, 111 in the sibutramine group and 121 in the placebo group.
Both groups received advice on a hypocaloric diet. During the one-year follow-up the
dropout rate was 8% in the sibutramine and 11% in the placebo group. The mean
weight loss was significantly larger in the sibutramine group (7.3%) than in the placebo
group (2.4%). There was no significant difference in any RAND-36 score between
groups during the follow-up. Both groups reported improvement in physical functioning
and health-change since last year. A ≥ 15% maintained weight loss was associated with
a cluster of HRQL improvements (physical functioning, general health, vitality, and
health-change since last year). Those with good emotional role functioning and good
social functioning at baseline and improvement in physical functioning and vitality92
during the first 3 months of study achieved the largest maintained weight loss at 12
months.
Study V included 74 obese patients entering weight loss surgery. Gastric bypass was
the operation for 48 (mean BMI 46.4 kg/m
2) and vertical banded gastroplasty for 26
(38.4 kg/m
2). During the one-year follow-up, the dropout rate was 25% in GBP group
and 15% in VBG group. Weight loss at 12 months was 34.0(10.2)% and 26.1(5.9) for
GBP and VBG, respectively. During follow-up all SF-36 scores increased markedly in
both groups. The effect sizes were larger for physical than mental HRQL scales. At the
end of follow-up, the mean scores on SF-36 were similar to the Swedish normal weight
general population and ≥ 50% of patients reported optimal HRQL in physical
functioning, physical role functioning, bodily pain, emotional role functioning, and social
functioning.
Final concluding remarks:
1.  HRQL was poor among patients entering weight loss treatment. All aspects of
HRQL (physical, mental, and obesity-related) were deteriorated.
2.  Poor HRQL was improved with maintained weight loss regardless of the weight loss
method.
3.  The larger the maintained weight loss the greater the improvement in HRQL. HRQL
responses were dependent on the amount of weight loss. A ≥ 5-10% weight loss
was needed to improve physical functioning and obesity-related psychosocial
problems, and ≥ 10-15% was needed to achieve a cluster of HRQL improvements.
4.  Some of the HRQL improvements were transient. In the 2-years after treatment, on
average only improvements in physical functioning and obesity-related problems
were sustained.
5.  Weight regain after treatment was associated with HRQL deterioration, but those
gaining back more than they lost still reported some improvement in social
functioning and obesity-related psychosocial problems at 2 years after treatment.
6.  Sibutramine did not produce HRQL benefits over placebo when measured with a
generic instrument.
7.  Gastric bypass and vertical banded gastroplasty led to marked weight loss and
improvement in HRQL The effect sizes of HRQL changes after surgery were larger
than with other weight loss methods studied.
8.  Not all the changes in HRQL were correlated to weight change. Other factors than
weight loss may affect HRQL responses. These include at least the changes in
physical activity and glycaemic control as well as the therapeutic effect of
participating in the treatment programme.
9.  Some HRQL measures were predictive of success in weight loss maintenance.93
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